o2h Discovery Brochure 2026

Seeding New Ideas...

A proprietary operating system for fast tracking new ideas to a development candidate

We are an insight driven multi-modality integrated drug discovery platform. A unique workflow that combines novel in-house capabilities with leading strategic partnerships embedded on an AI backbone. Our co-discovery models are customised to match your funding milestones.

WELCOME...

Alchemy - From Idea to a Development Candidate..

One of the most exciting things about drug discovery is that it never really stands still. We are now seeing a convergence of new technologies, modalities, and approaches change the way we think about discovering medicines, often in ways we could not have predicted. Yet the underlying challenge remains the same: how do we take a promising scientific idea and give it the best chance of becoming a meaningful candidate for a medicine?

Today, for example, we see chemistry and biology come together with AI, NAMs, conjugates and ADCs to create increasingly connected discovery programmes. I also see an important role for the alchemy between different disciplines, bringing together the right expertise, technologies and perspectives to create something greater than the individual parts. That is the proprietary workflow or operating system we have built at o2h co-discovery.

We work alongside biotech innovators, academic groups and pharma organisations at every stage of their discovery journey, shaping our approach around what each programme actually needs to align with the next funding milestone. For me, the most rewarding part is seeing these collaborations develop, from an early scientific idea through experiments, learning and iteration toward a programme with real potential.

As discovery continues to evolve, I believe the strongest programmes will come from bringing together the right people, expertise and ideas, and giving them the space to challenge, learn and build together. That is the kind of discovery culture we want to create at o2h.

Lastly, yes, we love working with inventors, but we are also part of an ecosystem of inventorship. We want to play our part in contributing to novel science and medicine, and to the ecosystems that support inventorship.

Prashant Shah, CEO, o2h Discovery Co-CEO, o2h Group

We @o2h have a mission to seed new ideas in life science and tech, directing our work with clear meaning. The purpose is to contribute to novel science to address unmet therapeutic need through funding, incubation, and collaborative execution.

We are engaged in pre-clinical research between idea generation and the identification of a lead/development candidate, using our core strengths in chemistry, biology and technology.

We recycle resource, energy, gratitude and love into the heritage ecosystems from where we have emerged and the global innovation ecosystems that we inhabit.

o2h group’s vision is to be the best at seeding new ideas in life science and technology by co-investing, co-creating and co-executing across boundaries

#o2hcollaborativeinnovation discovery

A multimodality integrated drug discovery platform to support our collaborators developing the next generation of therapies.

ventures

An S/EIS fund focused on seeding early stage biotech therapeutics and related AI opportunities.

technology

Customised software development services including both web and mobile apps covering all phases from design, build to adoption.

incubator

Shaping one of the region’s most exciting community of entrepreneurs in life science, technology and green innovation.

community o2h group is a community aware company and has been working with various organisations on a number of programs.

therapeutics

Novel co-curation, risk share, spin in-out of unloved/novel pre-seed ideas and IP for later seed stage funding.

but why bother?

because at o2h we love working with fearless innovators from any background with a collective passion we design and shape new discoveries that impact the world in which we live.

external collaboration we don’t need to do everything ourselves and are comfortable with different levels of control in a collaboration necessary in order to innovate.

Light collaboration

Deep collaboration

seeding new ideas by triaging funding, execution and incubation

What we do is supported by where we operate and our working mentality

It is embedded in simple human values that drive our habits, reflexes and attitudes to our work, each other and our community.

These 7 highlight a key piece of our human identity

Here the atmosphere is really electrifying

If you win, we win, and we have played our part in seeding new ideas in life-sciences, and finding patient cures…

Golden rules for collaborator 1 communication

Keeping promises

Did you do what you said you were going to do? [“I hear ‘fine, fine, fine, or ya, ya, ya’ and then nothing”]

Insight

Are you giving insight/analysis for fast decision making or only giving them data/information/unexplained attachments?

manager time 3

Save your collaboration

What are you doing everyday

Insight to make the life of your collaboration manager easier everyday and allow them to process their work faster?

Are you giving insight/analysis for fast decision making or only giving them data/information/unexplained attachments?

Are you managing expecta- 5

Advanced real time updates tions via frequent real-time updates and informing of problems/ solutions? [colleagues/collaborators don’t like surprises]

Error free

Is your work error free (attention to detail), what process checks and balances were designed in to your processes and system?

Learn from error

Were mistakes cleanly admitted to the colleague/collaborator and did you quickly offer a strategy for improvement if there was an error?

Direct insight from the ground

Is the collaborator exposed to live insights of troubleshooting evidence from the ground team and via literature search based research?

Innovation & Ingenuity

Are you showing sharpness in innovating the way in which we communicate and deliver the projects?

Plan B

Do we have a plan B or C are we communicating the alternatives/troubleshooting efforts logically so it appears strategic and not mechanical?

Team strength in depth

Does the collaborator see the strength in depth of capabilities by being exposed to communications from scientists/techies working at the ground level?

Expectations & Targets

Are you adapting to the latest changing expectations and targets of colleagues/collaborators and what is happening in their project/business?

A proprietary operating system for fast tracking new ideas to a development candidate

We are an insight driven multi-modality integrated drug discovert platform. A unique workflow that combines novel in-house capabilities with leading strategic partnerships embedded on an AI backbone. Our co-discovery models are customised to match your funding milestones.

• Chemistry
• Medicinal & Synthetic Chemistry
• Small Molecules & Peptides
• PR&D/Scaleup
• Library Synthesis
• Degraders, Glues, ADCs, LNPs
• Biology & DMPK
• Compound Screening
• Target Validation, Mechanistic Studies
• Biophysical/Biochemical and cellular assays
• Phys-chem & In vitro ADME Profiling
• In vivo PK/Tox/Efficacy Partnership

integrated discovery

• THE IDEA
• Chemistry
• Wet Lab Core
• MedChem & Small Molecules
• TPD & Libraries
• ADC & Conjugates
• Peptides & LNPs
• Green Chemistry
• Biocatalysis & Impurities
• Design &
• Execution
• Capability
• Novel In-house
• Novel Platform Tech Partners
• Study Partners
• Proprietary Fragment Library
• Glues - (Ternary Tx, Stick Tx)
• ADCs - (Spirea)
• LNP Formulation - (Camgene)
• Computational - (Linchpin.bio, ODD)
• Fragment Libraries - (Astex)
• Compound Libraries - (Enamine)
• AI Backbone
• Co-Discovery Models
• ELN, CITC, Agents
• Lab-in-the-loop Tech
• Predictive Model Partners
• Awards & Guarantees
• Risk Share
• (Inflexion

Chemipedia - Reaction Data Mycelium - Agentic Lead Compound Analysis

Molecule Discovery - (Deepmirror) Retrosynthesis - (SciFinder, Chemical.AI)

• Kickstarter, Delivery Guarantee, Match Funding
• Sweat Equity, IP share, Milestone
• Culture

To take you on the journey from idea to development candidate, we have in-house capabilities comprising proprietary tools, strategic partnerships and technology platforms. We combine these with AI at each stage where appropriate, integrating human effort, hybrid tools and fully automated systems. Additionally we offer a range of business models that enhance capital efficiency, helping you to get to the lead candidate.

• Biology
• DMPK
• Cascade Design
• Cellular Assays
• Screening & Automation
• Target Validation
• MOA & Engagement
• Bioanalysis & Phenotypic Screening
• RNA Biology
• Membrane Proteins SPR
• Mitochondrial
• Psychedelics
• ADCs & PDCs
• AUTOTACs & DUBTACs
• Novel E3s
• NAMs
• Cell Painting Assays
• Neuroinflammation
• Phys-Chem Assays
• ADME Drug Profiling
• Safety & Toxicology
• Metabolism & DDI
• Bioanalysis
• Pre-formulation
• Discovery PK
• PR&D Scale-up
• LEAD / DEV CANDIDATE
• Route Scouting
• Process Safety & Optimisation
• Impurity Control
• Non-GMP g to kg
• Tech Transfer & GMP Support
• DEL - (HitGen)
• Protein Production - (GenScript)

3D Organoids & Engineered Tissues - (Biodimensions)

• Omics - (Strand Life Sciences)
• Structural Biology (NCBS)
• NAMs (AZ)
• In-vivo - (Vipragen)
• hERG - (Metrion, ApconiX)
• AMES - (RCC Labs, Adgyl Lifesciences)
• Efficacy Models - (Pharmidex)
• Non-GMP (kg-scale) - (Ami Lifesciences)
• GMP - (Ami Lifesciences)

Cellular Pathways, Genomics, and Repurposing - (AI-VIVO) AI Biology Integration (IIT Madras)

In Silico Tox - (Consone AI) In Silico ADME - (Inductivebio)

Ternary Model Formation

To take you on the journey from idea to development candidate, we have a unique three-part ternary model combining novel capabilities (in-house/strategic third-party/ tech platforms), cutting-edge AI tools (mixed in with human experience), and business model to fit your stage of capital evolution.

Digitisation ELN CITC – Project Mgmt. Inventory Search

‘Mix in’ Human Experience Superstar talent Senior team Use brains and tools...

Proprietary AI Backbone & Digitisation

Novel Tech Partners Phoremost, Stick Tx, Astex Ternary, ODD, Spirea See o2h Ventures Portfolio.. .

Novel In-house TPD/Glues/TACS Conjugates - (ADCs, PDCs...) Phenotypic Screening/Cell Painting Novel/Niche Assays - (Integrin, Cha - melogK, Neurite, Semarion, SPR, RNA, Mitochondrial, Psychedelics...)

Design & Execution Capability

• Novel AI Tech Partners
• SciFinder, Chemical.AI Deepmirror Inductivebio Ignota Labs
• Models
• Risk Milestones/Buy-out IP share Sweat Equity
• Awards Kickstarter Biology Match Funding

Services FTE, FFS Plug-in Biotech

Strategic Partners DEL - (HitGen) In-vivo - (Vipragen) Comp chem – (Linchpin.bio, ODD ) hERG - (Metrion) Organoids - (Biodimensions )

Extensive Track Record of Collaborations in Biotech o2h discovery has supported marquee biotech and pharma across the globe since 2004.

• USA
• Big Pharma / Biopharma
• Biotech / Therapeutics

• TechBio / AI / Computational
• Research / Academia
• Investors / Enablers
• UK/Europe
• Big Pharma / Biopharma
• Biotech / Therapeutics

• TechBio / AI / Computational
• Research / Academia
• CRO / CDMO / Services
• Academic tech-transfer

• Japan
• Big Pharma / Biopharma
• Biotech / Therapeutics
• Singapore
• Big Pharma / Biopharma
• TechBio / AI / Computational
• Australia
• Academic tech-transfer
• Taiwan
• Biotech / Therapeutics

What Our Customers Say...

My relationship with o2h Discovery is now more than a decade. I have had many opportunities to collaborate with the o2h team for my drug discovery efforts at Karyopharm, Protai and Sporos Bioventures. I have always been impressed by their efficiency to deliver novel chemical compounds that helps to achieve targeted project milestones. Real time and insightful communication is also their key differentiator.

Sharon Shacham Co-founder & MD, E44 Ventures

Our relationship with o2h over many years supporting our medicinal chemistry projects in QEDDI has been highly productive. With o2h’s help we have progressed our portfolio to an advanced stage ready for partnering. We are very pleased with the efficiency, productivity and communication with o2h chemists and look forward to further positive outcomes.

Brian Dymock Head of QEDDI

At Cellestial, our goal is to maximise patient benefit that our treatments can offer. Small molecule therapeutics remain the most scalable form of treatment modality, meaning that more people around the world can benefit from them. We are proud to partner with o2h to expand our pipeline of astrocyte-protective small molecule drugs. The expertise provided both on the conceptual planning stage as well as the synthesis efficiency is world-class.

Dr Nat Hastings CEO, Cellestial Health

We had a great experience working with o2h discovery on our Fragment libraries project. Their expertise in conducting fragment-based screening, targeting dual series threonine kinase on surface plasmon resonance, was impressive. The efficiency, productivity, and detailed communication from the o2h biologist team were outstanding. We look forward to further positive outcomes in our future collaborations.

Eran Seger CEO and Co-founder, Protai Bio

Persephoni Biopartners is excited to announce the award of the o2h Kickstarter Program to InnoVira Therapeutics, a Persephoni portfolio company focused on developing small molecule medicines. The Kickstarter award will accelerate our early discovery and drive generation of candidates for our lead program. The high quality medicinal chemistry services provided by o2h Discovery are uniquely designed to help startups such as InnoVira reach value milestones more rapidly, which aligns closely with Persephoni’s core mission of de-risking early stage companies to bring novel therapies to patients faster.

Hilary Schultz CEO, Persephoni Biopartners

Chemistry Capabilities

We have deep chemistry expertise in medicinal chemistry, and various modalities to support a HIT ID to lead optimisation program complemented by strong HTE experience.

* Service in planning phase **Electrochemistry and Photochemistry reactions can support green chemistry approaches…

Chemistry Lab

Shirish Research Centre o2h discovery has launched a new state-of-the-art research centre with chemistry, biology, Scale-up, process and ADC capabilities to support integrated pre-clinical drug discovery programs.

Shirish Research Centre

discovery

discovery

Hauxton Meadows

Coming Soon...

Hauxton Meadows o2h discovery will launch the Hauxton Meadows housing early-stage science incubators which will feed into the large-scale spaces in the Cambridge eco-systems as they grow in scale. The building will contain 8 standard module laboratories that will have around 12 Biologists working in each of them.

Hauxton Meadows incubator

Integrated Drug Discovery (IDD)

Deep scientific knowledge, expert management and a thorough understanding of the drug discovery challenges

Discover a comprehensive suite of capabilities to propel your drug discovery program from target validation to IND submission. We offer more than just multiple services.

Our integrated approach combines deep scientific knowledge, expert management and a thorough understanding of the drug discovery challenges.

“Have always delivered and we particularly appreciate their philosophy of working towards the success of the partner organisation and not just the work plan.”

Bob Boyle CEO, Sentinel

Target Identification & Validation

Drug discovery starts with finding the right biological target and confirming that modulating it can deliver real therapeutic benefit. We have experience supporting drug discovery endeavours from inception through to pre-clinical model studies. We deploy integrated cellular, biochemical, and mechanism-based assays to confirm target relevance and disease linkage laying the groundwork for robust progression into hit discovery.

Hit Identification

At o2h discovery, we tailor high-quality hit-finding strategies across diverse target classes, including challenging “me too” and “undruggable” targets. Leveraging biochemical, biophysical, and high-throughput cellular platforms, we deliver high-confidence hits with clear on-target engagement and actionable SAR to accelerate drug discovery.

Hit-to-Lead

At o2h discovery, we accelerate hit-to-lead development through rational design, SAR confirmation, synthesis, biological assays, and early ADMET studies. By integrating pharmacology, DMPK, and medicinal chemistry, we enable faster design-make-testanalyse cycles, empowering biotech partners to make informed Go/No-Go decisions and advance molecules addressing unmet medical needs.

Lead Optimisation

Lead Optimisation is a critical phase in the drug discovery and development process. During this stage promising lead compounds typically identified during the hit-to-lead phase undergo extensive refinement and optimisation. Our multidisciplinary approach enhances lead compounds via structure-guided design, ADMET fine-tuning, pharmacokinetic profiling, and safety assessment transforming leads into preclinical candidates.

Fragment Based Drug Discovery

Unlock the potential of undruggable targets with o2h discovery’s Fragment-based drug discovery services

Fragment-based drug discovery has emerged as a revolutionary approach to identifying novel chemical starting points for a wide range of biological targets, including those once considered undruggable.

By utilising smaller, basic building blocks known as fragments, this cutting-edge method offers unique advantages in the search for potent drug candidates.

“We have worked with the o2h team on a range of synthetic projects and had consistently positive experience. The combination of competence, effective project management and detailed documentation made us go back again and again.”

Professor Kirill Alexandrov CSIRO, QUT Synthetic Biology Alliance

Medicinal Chemistry

We work at the critical interface of chemistry and biology, partnering with global biotech and pharma companies to accelerate the development of innovative therapies

Overview

Our medicinal chemistry expertise spans the full spectrum of small molecule design and synthesis, from traditional heterocyclic and carbocyclic chemistry (including carbohydrates and steroids) to complex modern modalities. These include PROTACs, molecular glues, peptides, and oligonucleotides, where our integrated approach helps advance even the most challenging drug discovery programs.

By combining deep scientific knowledge with flexible collaboration models, o2h Discovery enables partners to efficiently scale their research, reduce timelines, and bring breakthrough medicines closer to patients.

Why Partner with o2h Discovery for Medicinal Chemistry Service?

o2h Discovery offers end-to-end medicinal chemistry services, including hit identification, hit-to-lead optimisation, lead generation, and lead optimisation. Our services can be accessed as standalone projects or integrated within a complete drug discovery program.

We combine chemistry and biology expertise to design and synthesise high-quality compounds, establish structureactivity relationships, reduce liabilities, and advance molecules toward in vivo proof-of-concept. Our teams collaborate closely to ensure compounds meet target product profiles while supporting ADME, PK/PD, and pharmacological studies.

Global expertise with operations in India, UK, and USA

Integrated drug discovery model combining medicinal chemistry, biology, and DMPK

Proven track record in hit-to-lead and lead optimisation program

Flexible, agile, and collaborative engagement structures

Strong emphasis on IP protection and scientific integrity

ADC – Different Linker Synthesis Experience

We have the capabilities to design and synthesise novel ADC linkers and linker–payload architectures

In recent years, we have continued to strengthen and expand our ADC discovery capabilities, supporting multiple client programs across linker design, payload chemistry, and conjugation technologies. Our

Examples of payloads we have worked with include:

growing expertise enables the development of complex ADC components from early-stage design through synthesis and characterization.

• Exatecan
• SN38
• MMAE
• Duocarmycines
• Triptolide
• Our ADC capabilities include:

Design and synthesis of cleavable and non-cleavable linkers (Val-Cit, Val-Ala, disulfide, List of cleavable ADC Linkers – easy access of these linkers glucuronide, PEG, click chemistry, and maleimide/NHS ester), utilizing SPPS technology for the rapid synthesis, customization, and delivery of peptide-based linker libraries.

• Sr. No.
• Linker name
• S”r‘”‘re
• Sr. No.
• Linker name
• S”r‘”‘re

Development of linker-payload constructs and conjugation-ready building blocks.

Experience with a diverse range of payloads, including Exatecan, SN38, MMAE, PBD dimers, BCN-PEG-Val-Cit-

Elimusertib, steroidal and non-steroidal payloads, and other potent anticancer heterocyclic

• PABC- Payloa
• MC-Val-Cit-PABC-
• small molecules.
• Paylaod
• TCO-PEG-Val-Cit-

PABC- Payload

Design of peptide linker–payload conjugates to improve tumor-selective payload release and Clickable linkers minimize off-target exposure.

Development of Targeted Drug Conjugates (TDCs) incorporating SR48692-derived targeting cadaverine-Val-Citligands (receptor-targeting small molecules) and A1331852-derived payloads (potent apoptosis-

PABC- Paylaod

GGFG-linker inducing small-molecule payloads), integrated with optimized linker technologies for selective

PeLtide linker drug delivery.

Route scouting, optimization, purification (Prep HPLC/flash chromatography), and MC-A-B-C-Citcomprehensive analytical characterization (LC-MS, HRMS, NMR, HPLC, and chiral SFC).

• Malei ide-caLroyl-
• PABC- Paylaod
• Non-natural AA
• GGFG-linker linker

PeLtide linker

By combining expertise in medicinal chemistry, peptide synthesis, and analytical sciences, we provide integrated support for ADC discovery—from custom linker synthesis to complex linker-payload development—helping accelerate next-generation targeted therapeutics.

• Malei ide-PEGn-A-
• B-C-PABC- Paylaod
• PEGylated linker
• Glucuronide linker
• B-Glucuronidelinker

Examples of payloads we have worked with include:

• discovery
• Exatecan
• SN38
• MMAE
• Duocarmycines
• Triptolide

List of cleavable ADC Linkers – easy access of these linkers

• Sr. No.
• Linker name
• S”r‘”‘re
• Sr. No.
• Linker name
• S”r‘”‘rep. 1
• MC-Val-Cit-PABC-
• Paylaodp. 2
• cadaverine-Val-Cit-
• PABC- Paylaodp. 6
• BCN-PEG-Val-Cit-
• PABC- Payloa
• TCO-PEG-Val-Cit-
• PABC- Payload
• Clickable linkersp. 7
• GGFG-linker
• PeLtide linkerp. 3
• MC-A-B-C-Cit-
• PABC- Paylaod
• Non-natural AA linkerp. 8
• Malei ide-caLroyl-
• GGFG-linker
• PeLtide linkerp. 4
• Malei ide-PEGn-A-
• B-C-PABC- Paylaod
• PEGylated linkerp. 9
• Glucuronide linker
• B-Glucuronidelinker

Peptide Synthesis - Capabilities and Experience

A dedicated to advancing scientific research and drug discovery through exceptional peptide synthesis services

Our Peptide Platform

With cutting-edge infrastructure, expert scientists, and a commitment to speed, we remove the traditional roadblocks in peptide sourcing, ensuring your research moves forward and faster than ever.

State-of-the-art facility for peptide synthesis, purifcation, analysis and characterisation

Expertise in traditional solution phase and advanced solid phase peptide synthesis (SPPS)

Capabilities to generate library of standard average length peptides

20 -mer), as well as to deliver long chain (50 -mer) and complex peptides

Pepatde Midtficatio

In addition to synthesis, our experienced team of chemists also excel in performing a wide range of peptide modifcations, including but not limited to the followingg

• Linear - long chain peptides
• Acetylated
• Peptides
• Macrocyclic
• Peptides
• Branched
• Peptides
• PE ylated
• Peptides
• Di-sulphide bond formation
• Succinylated
• Peptides
• Head to Tail
• Cyclisation
• Lactam ring formation
• Stapled
• Peptides
• Additional
• Ser vices
• Assay Development
• (SPR, FP, ChamelogK)
• Titration (Acid-Base
• & Karl Fisher)
• Solubility
• Testin g
• Chromatography
• (æPäC, åäC, çC, àC)
• pH Adjustment and Amino
• Acid
• Analysis
• Chromatography with LC-MS/ESI
• Metallic Analysis
• (ssy, Ikv, IkvlMy)
• Spectroscopy
• (UV VIs, IR, NMR)
• Counter —on ˜•changš

chemistry discovery

Nucleoside – Nucleotide Chemistry

We specialise in precision synthesis of nucleoside and nucleotide analogues, backed by advanced analytics

Nriamittnml ecaigrmt

Ribose and Base Modifcation: Enhancing stability and functionalityy

• Uracil/Cytidine
• Adenosine
• Guanosine

C-linked Nucleosides: Improving pharmacokinetics and biological activity.

Nriamintnml ecaigrmt

NMP, NDP, NTP, N4P, Thio-phosphate:

Custom synthesis for biochemical and therapeutic applications.

DmnticnmnlPrttficntielcenl ecalntical etntrument

Ensuring high quality and purity of synthesized compounds.

High Throughput Experimentation (HTE) & Library Synthesis

Our scientific team specialises in HTE for diverse chemistries, covering reaction screening, synthesis, purification, and library delivery

Technology & Infra Support

Catalyst Kits – Pre-packaged kits for rapid reaction screening and optimisation

Parallel Reaction Stations – Radleys Carousels

Parallel Reaction Blocks – 6, 10, 12

Pressurized Vessels (for parallel hydrogenation, reduction, carbonylation type reactions)

• Robotic Microwave Systems
• Photo Reactor Systems
• Peptide Synthesizers
• Flash Purification Systems
• Prep HPLC Support
• SFC Support
• SCX Cartridges
• Ion Exchange Resins
• Chemistry Range
• Suzuki Coupling
• Buchwald Coupling
• C-H Activation
• Pd-mediated Cross Coupling
• Acid-Amie Coupling
• Acrylamides
• Library Diversity Reagents
• Boronates
• Acids
• Amines
• Esters
• Alcohols
• Aldehydes
• Aromatic & Heteroaromatic Halides
• Thio Compounds
• Micro Chemistry New initiatives
• Parallel rxn Screening

Sub mg scale rxn (48 to 96)

• LCMS Monitoring
• Heatmap Data Generation
• Quick Decision Making

1500 compound library delivered with ~93% success rate, for a UK based big pharma

Targeted Protein Degradation

We have expertise in PROTAC services and synthesis for targeted protein degradation and integrated drug discovery o2h discovery has a customisable “off-the-shelf” PROTAC Toolbox

TM consisting of a diverse set of linkers, E3 ligands and functionalised E3 ligand-linker compounds to jumpstart design, synthesis and testing/screening novel protein degraders.

“We’ve worked with o2h for a long time now as partners, and I particularly pick out their PROTAC expertise in synthesis, purification, and also testing the stability of PROTACs once they’ve been made.”

Julian Blagg Executive VP, Drug Discovery, Neophore

Lipid Nanoparticles (LNPs)

Specialising in the synthesis of diverse phospholipid molecules from mg to multi-gram scale o2h has acquired extensive expertise and capabilities to conduct the synthesis, purification and analysis of diverse and intricate lipid containing molecules, from low milligrams to multi-gram scale.

Our analytical team utilises a range of analytical methods, such as CAD HPLC, to purify and assess these products, ensuring high levels of purity are achieved.

“We understand that lipid chemistry is complex and requires significant expertise in synthesis, purification, and analysis. Therefore, we looked for a competent and reliable CRO partner to support our requirements and found o2h discovery. We have now done several projects with o2h.”

Bharat Majeti Head of LNP technology, RVAC Medicines

Advancing Next-Generation Covalent Inhibitors

Harnessing Scientific Expertise and Drug-Discovery Experience to Target Complex and Intractable Diseases

Covalent inhibitors offer distinct advantages over traditional reversible inhibitors, including enhanced potency, prolonged target engagement, time-dependent pharmacology and the ability to modulate challenging targets that lack well-defined binding pockets or are driven by transient or shallow binding interactions. When appropriately designed, covalent mechanisms can also enable improved selectivity through controlled reactivity and precise residue targeting.

At o2h discovery, we have capabilities to support the design and development of next-generation covalent inhibitors, spanning both targeted covalent and reversible covalent modalities, with the potential to address complex and previously intractable targets.

Our multidisciplinary teams offer integrated expertise in covalent drug discovery, including informed covalent warhead selection and medicinal chemistry strategies to finely tune intrinsic electrophilicity, steric accessibility, and leaving-group behaviour in order to define the minimum reactivity needed in the warhead and reduce the risk of off-target activity. We have established experimental biology capabilities such as jump-dilution assays to distinguish irreversible from reversible inhibition and to assess the durability of target engagement under enzyme-turnover conditions. In parallel, our ADME team provides the GSH reactivity assay to evaluate intrinsic electrophile reactivity and support early de-risking of off-target liabilities; additionally, the assay has been extended to include GST-mediated conjugation, providing a more physiologically relevant read-out for assessing metabolism-linked reactivity risks.

Through a strong understanding of protein–ligand interactions (including covalent binding geometry and residue microenvironment effects) and modern synthetic capabilities, we seek to deliver tailored solutions that may enhance target engagement and support sustained, mechanism-driven therapeutic effects.

Potential areas of support in covalent inhibitor discovery include:

Identification and optimisation of covalent warheads across multiple electrophile classes

Design and synthesis of selective covalent inhibitors with a focus on balancing potency, selectivity, and reactivity

Support from concept through to preclinical development including hit-to-lead and leadoptimisation phases

Development of residue-specific warheads, targeting cysteine as well as other residues such as lysine, tyrosine, and beyond (including serine and threonine where mechanistically appropriate)

Mechanistic characterisation of covalent binding through kinetic, biochemical, and cellular assays

Early developability assessment encompassing metabolic stability, permeability, and safety-relevant reactivity profiling

Should you wish to discuss how we might support your project, please contact us at [email protected]

Analytical Chemistry

Comprehensive Analytical Support Across the Entire Discovery and Development Cycle

Expertise

Basic Analysis: Comprehensive HPLC (Chiral & Achiral), LCMS, mass spectrometry, and NMR services for qualitative and quantitative analysis.

Structure Characterization: Expertise in NMR data interpretation, LCMS/MS analysis, and developing expertise in amino acid sequencing by MS/MS for peptide compounds.

Purification: Specialization in the purification of PROTACs, peptides, and lipids, including UV-inactive compounds up to gram scale.

Chiral Separation: mg to g scale chiral separations, a wide range of chiral stationary phases (CSPs), and high-efficiency SFC.

Advanced Studies: Property determination, including Chamelog K, Chromlog D, and impurity/ product quantification.

Equipment

Spectroscopy: NMRs for 1H, 13C, 2D & QNMR analysis, UPLC-MS, direct mass with MS/MS capabilities, HR-MS/MS, ICP-MS & FTIR (outsourced).

Liquid Chromatography (LC) Systems: HPLC-PDA, 1 UPLC with PDA/CAD, HPLC- ELSD.

Purification: Specialization in the purification of PROTACs, peptides, and lipids, including UV-inactive.

Preparative/Purification Systems: Prep HPLC (with Auto purification), Analytical/Preparative SFCs (UPC2 & SFC Investigator for semi-purification (multiple columns and solvent selectors), Waters SFC 350 for Chiral separation).

Thermal Analysis: DSC 5+, TGA (outsourced).

PR&D and Scale-up Services

From lab-scale R&D to large-scale production (g to kg)

In our 20+ years of experience working on fast-paced drug discovery projects with companies across the globe, we have prepared thousands of new chemical entities. We put this experience together, along with our talented staff and high-end infrastructure, to offer high-quality and cost-effective services for your ‘development’ projects

Key Highlights

The Non-GMP PR&D lab designed to ensure safety and operational efficiency The kilo lab has a full range of 20L, 50L, and 100L jacketed glass reactors Temperature ranging from -35 °C to 200 °C State-of-the-art glass reactor assemblies incorporate advanced features Utilisation of flame-proof connections and static discharge mechanisms Equipped with Thermal Screening Unit and Differential Scanning Calorimetry Per batch manufacturing output from grams to lower kilograms

Our Offerings

Flash purification machine to support large scale purification Route scouting for novel, cost-effective, and scalable ROS Process development and optimisation for pre-clinical supplies Scale-up of intermediates, building blocks, and final targets Analytical method development & large-scale purification support Synthesis, isolation, and characterisation of process impurities TSE/BSE certification and metal content analysis Milestone-based project tracking with thorough and real-time communication Supply of detailed tech pack with active assistance for technology transfer A dedicated analytical team to support real time QC and method development GMP Synthesis Support (via channel partners)

A comprehensive range of equipment (Analytical, Reaction Technology and Purification) for ‘speed’ of project delivery:

From Our Labs to the Clinic & Market

The real-world impact of o2h Discovery’s scientific contributions – translating partner programmes from early chemistry into the clinic and onto the market.

• 30+ Marketed Drugs
• Clients with 148+ Clinical Trials
• Clients now in 22+ Clinical Assets*
• High-Attribution

Spotlight – Deep o2h Engagements now in the clinic or market

• Storm Therapeutics
• 7+ yrs
• Oncology

METTL3 inhibitor programme → B1-9321 in Phase 1/2 AML

Chemistry FTE from lead generation through to scale-up

• Sentinel Oncology
• 6+ yrs
• Oncology

ATR kinase inhibitor → Phase 1/2 in oncology

Chemistry & biology from lead optimisation to candidate

• Arrakis Therapeutics
• 8+ yrs
• Oncology

RNA-targeted small molecules → multiple Phase 1 assets

57 FTEs - 4 o2h-synthesised compounds in Arrakis patents

• Heptares/Nxera
• 6+ yrs
• CNS

Multiple GPCR programmes → HTL0016878 in Phase 2

• Multi-programme GPCR chemistry partnership
• NeoPhore
• 8+ yrs
• Oncology

MMR pathway chemistry → NEO-201 Phase 1 oncology

Chemistry FTE, FFS, DMPK, PROTAC & scale-up

Karyopharm

MARKETED

XPO1 inhibitor lead opt → Xpavia (selinexor), FDA 2019

• Chemistry FFS contribution from ~2009-2010
• Therapeutic Areas Served
• Oncology 34
• Immunology 7
• CNS/Neurology 6
• Rare Disease 4
• Ophthalmology 3
• Anti-infective 3
• Dermatology 3

How we at o2hHow we at o2h leveraging Generative AILeveraging Generative AI

Optimising Research, Enhancing Collaboration, &Optimising Research, Enhancing Collaboration, & Accelerating Drug Development with Generative AI.Accelerating Drug Development with Generative AI.

AI and LLM Integration for R&D

Our tech team conducts research and development on AI tools and Large Language Models (LLMs), exploring their integration across all stages of the drug discovery process to enhance efficiency, innovation, and outcomes.

Accelerating MVP builds with GenAI

Fast Tracking ADME Analysis

Upskilling team with GenAI

Using GenAI to speed up coding, test ideas faster, and turn concepts into working models quickly and efficiently.

Partnered with an AI company to integrate ML and GenAI for faster ADME analysis predictions, helping collaborators save time and resources by focusing on shortlisted studies.

Training internal teams to leverage GenAIfor communication and research, streamlining processes to reduce overall R&D timelines.

Our Vision with GenAI in the Next 5 Years

To be at the forefront of AI-driven drug discovery, setting new standards in efficiency, innovation, and security within the CRO industry.

AI-Integrated Pipelines

Develop workflows with AI for seamless data analysis and decision-making.

Enhance CITC with AI capabilities for efficient chemical and project management

AI-Driven Collaboration

Build strategic partnerships with AI technology providers and research institutions to drive innovation.

Security and IP Protection

Implement robust data encryption and access controls for AI-generated insights.

Collaborate with clients to safeguard proprietary data during AI model training and deployment.

Talent Development

Train teams to master both AI tools and traditional scientific methodologies for a balanced approach.

IP Security – 6 Major Phases of Project Lifecycle

We understand the responsibility to protect the IP of our clients during a formative stage of the process

• Laboratory & Office Processes
• Card Key Access
• Designated Lab & Write up areas
• Individual LNBs & Drawers
• Computer & Technology
• Designated Computer Systems
• Unique Login ID & Passwords
• Designated Project Place & Folders
• Legal Compliance o2h IP Policy
• In-house QA Team
• QA/IP clearance on exit
• Employment letter with confidentiality clause
• Rigorous handover process
• Project Setup Processes
• 2-way CDA
• Project Introduction form
• Project Code Name & Password
• Collaborator Communication
• Project Place on Secured Platform
• Exchange of Password protected documents
• Site Security
• Private & Secured On-site Server
• Firewall & Secured VPN
• Daily Back up
• Permission Controlled Access

Green Chemistry

Implementing eco-friendly practices from synthesis to analysis on the bench discovery

Maximise Atom Efficiency

Shorten synthetic routes to reduce by-products

Close reaction monitoring for high yield & < waste

• Apply validated high-yield processes to scale-up
• Use of Safer Solvents & Conditions
• Greener solvent selection
• Solvent recovery, recovery and minimization

Methods with shorter columns – save time/waste

• Automation in Analysis
• Automated systems to prevent errors
• Avoid pre-treatment steps to reduce waste
• Combine analytical processes to save resources
• Prevent Waste at Source
• Optimise/substitute routes for hazards/Waste
• Optimized inventory control
• Waste segregation protocols
• Design Safer Chemical Synthesis
• Catalysis over stoichiometric methods

In-house checks/peer review of route for safety

• Effective literature review to reduce inventory
• Efficient Sample Analysis
• Minimise sample sizes for analysis
• Integrated analysis
• Direct detection methods

Clinical Bioanalysis & Translational Sciences

An experienced scientific team supporting clinical and preclinical development programs from candidate selection through clinical proof-of concept. Supporting global partners across small molecules, peptides, biologics and emerging modalities through scientific oversight, bioanalytical strategy, study management and data driven decision support.

Support

Clinical Bioanalytical Strategy

Support bioanalytical planning across 01 Phase I-IV studies, PK/PD endpoints, biomarkers, immunogenicity assessments and regulatory expectations.

Science

IND-Enabling Development Support

Scientific oversight of ADME, PK, toxicology, safety pharmacology and genotoxicity programs supporting 02 candidate progression and regulatory submissions.

Quality

Data Interpretation & Decision Support

Integrated review of PK, PK/PD, toxicology and bioanalytical datasets to support program decisions and portfolio progression.

Operations

CRO & Study Management

Identification, qualification and management of specialist CRO partners with end-to-end oversight of timelines, 03 quality and study execution.

Partnership

Cross-Functional Scientific Partnership

Embedded collaboration with medicinal 05 chemistry, DMPK, biology, regulatory and clinical teams to connect data with development strategy.

Assurance

Regulatory & Submission Readiness

Support for study reports, data packages, regulatory interactions and audit-ready documentation throughout development.

Novel Biology Capabilities

Advancing Next-Gen Novel Biology Capabilities @ o2h discovery

PLATFORM

NAM & Advanced Models

New approach methodologies replacing traditional in vivo systems

3D Models - physiologically relevant tissue architecture

Spheroids - scalable 3D cell aggregates for screening

• Organoids - patient-derived disease modelling
• Organ-on-a-Chip - microfluidic human-relevant systems
• DEGRADATION
• Targeted Protein Degradation
• Next-generation modalities for the undruggable proteome
• Molecular Glues - induced proximity therapeutics
• PROTAC Toolbox - modular bifunctional degraders

Novel E3 Ligases - expanding the recruitable repertoire

AUTOTACs & DUBTACs - autophagy & stabilisation routes

FRONTIER BIOLOGY

Emerging Modalities

Expanding therapeutic reach across RNA, organelles & conjugates

RNA Biology - therapeutic targeting of the transcriptome

Mitochondrial Biology - bioenergetics & disease

Microglia - CNS innate immunity platforms

Multi-Omics - integrated genomic, proteomic & metabolomic insight

ADCs & PDCs - targeted antibody & peptide conjugates

Accelerating Non-Animal Models: A Strategic Venture

Regulation, science and cost are converging. o2h and AstraZeneca are establishing a dedicated NewCo to industrialise non-animal models at speed — a co-creation model, not a vendor relationship.

Why now? Three forces are making NAMs the new standard

Regulatory Momentum

FDA Modernization Act 3.0 advanced through the US House in 2026, enforcing NAM adoption before human trials.

Scientific Maturity

Organ-chips, human iPSC assays and computational models now rival animal models in predictive power.

Ethical & Cost Pressure

Global pressure to reduce animal use is accelerating investment into humanrelevant, scalable alternatives.

Why o2h?

The right partner for industrialisation

Proven track record Two AZ academic summits on NAMs in India; years of collaboration across chemistry, bio-analytical, IDD and AI

Assay industrialisation capability Demonstrated ability to scale key assays across

Cambridge and Ahmedabad

Innovation ecosystem

Venture fund, science park and IDD capability with extensive biotech reach

Collaborative mindset Co-creation built into the structure — not a transactional vendor relationship

• Roadmap Immediate next steps
• Now
• Stakeholder buy-in within AZ
• Near-term
• NAM hackathon & legal setup
• Structure

NAM NewCo - proposed model o2h 80% majority equity

AZ 20% minority equity

£100k seed funding, pro-rata

AZ approval for CEO and board appointments

Access to venture capital, grants and licensing

Lighter-touch governance — faster decisions

Replicable model for other AZ innovation areas

• Launch
• High-visibility event (Cambridge / Parliament)
• Industry-wide NAM adoption target

Diverse Antibody Conjugate Formats

An Integrated Platform for Diverse Bioconjugates and Targeted Therapeutics.

• A Antibody–Payload Conjugation
• Classic ADC · Cytotoxic payload
• Cytotoxic
• Bispecific ADCs
• Dual-targeting antibody · cytotoxic payload
• Dual-target
• MMAE
• Ag1
• Ag2

Payload

Integrated review of PK, PK/PD, toxicology and bioanalytical datasets to support program decisions and portfolio progression.

Two distinct antigen-binding arms for dual tumour targeting — improved selectivity and internalisation efficiency.

Antibody–Oligonucleotide Conjugates

AOC · siRNA / ASO / miRNA

• Oligo
• E Dual-Payload ADCs
• MMAE/MMAF + SN-38 · site-specific

Dual MOA

Cell-targeted delivery of RNA therapeutics. Oligonucleotide synthesis and conjugation chemistry — a new modality for o2h.

• Antibody–Targeted Degrader Conjugates
• PROTAC / Molecular glue payload
• Degrader
• MMAE

SN-38

Two mechanistically distinct payloads on one antibody to overcome resistance. Site-specific cysteine chemistry (SH38/SW38 sites).

• Peptide–Drug Conjugates
• Bioactive peptide payload delivery
• Peptide Radioligand
• POI
• E3L

Targeted protein degradation via PROTAC or molecular glue. Addresses undruggable targets with o2h's existing degrader expertise.

Bioactive peptide payloads for receptor targeting, cell penetration or antimicrobial activity — leveraging o2h's in-house peptide platform.

Peptide-Scaffold Dual-Toxin Conjugates α-Helix scaffold · Lys / Cys orthogonal sites

• Tox1
• Tox2
• Lys
• Cys

DAR 1-4

A peptidic α-helix presenting lysine and cysteine at defined exposed positions, functionalised differentially to carry two distinct toxins at highly reproducible DAR. The resulting peptide is attached to an Ab or Fab.

discovery biology/UK

biology/India discovery

Biology Delivered

An integrated team of highly experienced biologists with a proven track record in advancing complex projects

Overview

At o2h discovery, we provide fully integrated biology services from our state-of-the-art facilities in Cambridge, UK, and Ahmedabad, India, to accelerate drug discovery programs. Our team of experienced Ph.D and Masters level scientists delivers high-quality results across a broad range of therapeutic areas. Leveraging advanced technology platforms, we support every stage from target validation to pre-clinical candidate selection.

Our biologists design and execute customisable assays to assess potency, efficacy, and mechanism of action (MOA) profiling. We foster a collaborative, cross-continental working model, ensuring seamless technology transfer between our UK and India teams. By combining academic insight with industrial rigor, we deliver faster, smarter research solutions.

State-of-the-Art Equipment

Our cutting-edge facilities are equipped with advanced tools to ensure precision and efficiency in biology research:

Biacore T200 SPR Incucyte Thermo CX7 LED Robotics Jess CytoFLEX S

FLIPR Penta Bio-Rad CFX96 Hamilton Star CLARIOstar Plus & PHERAstar Opentrons OT2

• Compound/Fragment Screening
• Biophysical/Biochemical and Cellular Assays biology discovery
• Target Validation, Mechanistic Studies
• Transporters
• GPCRs
• Enzymes
• Target
• Classes
• IonMChannels siRNA shRNA
• PROTAC
• NaLTSA
• CRISPR/Cas9
• Target
• Engagement
• NanoBRET
• NanoBiT
• Mitochondrial
• Integrins
• Psychedelics
• ProteinMProtein interactions
• Niche
• Expertise
• RNA biology
• ImmunoM oncology
• Neuroscience by target cEas“
• & disease by discovery stage
• Metabolic syndrome
• Immunology
• Therapeutic
• Areas
• Oncology
• Respiratory
• Cardiovascular diseases

DrugMDrug interactions and synthetic lethality ndruggable targets and genetic benchmarking

• Fragment screening
• Biomarker assessment
• Transcriptional studies
• Iterative screening
• Biophysical
• Assay
• Biology
• Cellular
• Biochemical
• SiteMdirected mutagenesis
• Binding studies
• Primary, orthogonal and selectivity
• Drug
• Screening

Phenotypic screening

Future direction: DNA Encoded Libraries (DEL), Antibody Drug Conjugates (ADC), Membrane Proteins, Proteomics, other TACs and Molecular Glues

Discover novel assays and blogs on following topics:

High-Content Imaging: A Transformative Approach to Drug Discovery

Exploring SPR and Fluorescent Dye Displacement Assays for RNA Binding

Small Molecule Therapeutics

PROTAC: o2h discovery’s Biology Expertise

Exploring Psychedelics: A New Frontier in Mental Health Research

Integrin Assays: Decoding Cellular Interactions

Revolutionising Drug Discovery: Harnessing the Power of FRET and BRET Assays

Unlock Advanced Flow Cytometry: Boost Research with the CytoFLEX S System scan to read

Assay Screening

We provide integrated screening services to fuel novel drug discovery programs

Our Capabilities...

Assay deveiopreitn optlrlsatloin aid vaildatloi

Screeilin uslin blocherlcain blophyslcain aid ceii-based forrats

• Hlt coifrratloin couiter-screeilinn aid seiectlvlty profilin
• Iitenratloi wlth
• AODCQODAU studles aid SAR expaisloi
• Automated Discovery Powered by OT-2!

To strengthen our Screening offering, o2h discovery has integrated the Opentrons OT-2 liquid handling robot, a fexible and customisable automation platform designed for reproducible, high-throughput workfowse

Key Features

Dual 8-channel multi-pipettes for accurate liquid handling down to 384-well plates

Absolute reproducibility in pipetting, minimising variability across large datasets

Customisable and programmable workfows adaptable to any throughput requirement

Supports compound dispensing, serial dilutions, cell seeding, hit picking, and nucleic acid protein extraction

Kit- and reagent-agnostic software, avoiding lock-in to expensive consumables

Reduced manual handling, saving time while eliminating human error

By incorporating OT-2, we enhance both throughput and data quality in Screening campaignse This automation-driven approach ensures faster cycles of design–make–test–analyse (DMTA), enabling biotech innovators to progress from hits to leads with speed, accuracy, and confdencee

Drug Discovery Through Biophysical Insight

Using fluorescence polarization, SPR, and thermal shift assays, we study protein binding, stability, and mechanisms

At o2h discovery, we deliver biophysical characterisation of ligand-target interactions and can aid in hit finding approaches using fragment-based screening. We can prove mechanistic insights, kinetic and thermodynamic profiling for your novel compounds. With a published crystal structure of your target of interest and in complex with its cognate peptide/molecule, we can develop customisable assays for small molecule screening.

We can design Fluorescence Polarisation (or) Anisotropy with labelled peptide or compound probes using high performance plate readers like CLARIOstar and PHERAstar. With label-free technology platforms like Biacore T200, we can establish more advanced studies like Surface Plasmon Resonance (SPR) providing vital kinetic data on ligand-target interaction like association-Kon, dissociation-Koff rates and KD determination. We can use simple techniques such as Thermal Shift Assay (TSA) to determine thermal unfolding and aggregation of the target protein using SYPRO Orange dye that binds to hydrophobic regions of the denatured proteins; illuminating the presence of unstable proteins in the absence of compound binding or target engagement.

In addition to the range of aforementioned biophysical methods, o2h discovery has well-established alliance partners to augment our capabilities and in providing tailored needs for your research project.

To know more about our biology services offering, please reach out to us at [email protected]

Cascade Design

A systematic arrangement of assays and models that progressively evaluate a compound’s efficacy, selectivity, and safety

Cascade Design: A Catalyst for More Effcient Drug Discovery

Progressing from hit to lead to preclinical development is fraught with challenges.

• Many candidates fail due to:
• Poorly designed or non-reproducible assays
• False positives from irrelevant models
• Lack of early Go/
• No-Go decision points

Weak translation from in-vitro t in-vivo outcomes o2h Discovery’s Cascade Design Approach

Integrated

We design cascades that drive progress through well-defned -o//o--o

Discovery Cascade checkpoints, reducing late-stage failures.

Progressive Assay

Design

Layering biochemical, biophysical, cellular, and in vivo assays to ensure biological relevance at every stage.

• STAR in Drug
• Development
• Incorporating
• Structure–Tissue
• Exposure/Selectivity–Activity
• Relationship
• (STAR)
• to align chemistry, PK /PD insights.
• Expert Decision

Framework

Our team applies the Dos, Don ts, and -o//o--o rules in assay design, helping collaborators avoid common pitfalls.

Why Partner with o2h Discovery

At o2h discovery, we support our collaborators by combining biology, chemistry, and DMPK expertise to build cascades that de-risk discovery programmes, accelerate candidate selection, and support the next generation of therapies addressing unmet medical needs.

If you d like to discuss your screening cascade challenges in more detail, we d be happy to set up a call

Write to us at:

[email protected]

ChameLogK Assay

Unveiling chameleonicity for PROTAC molecules o2h discovery; First in the World to Offer the ChameLogK Assay to our Clients...

o2h discovery is thrilled to be the first in the world to offer the ChameLogK assay to our clients. With the capability to quickly and inexpensively measure chameleonicity, this assay represents a significant step forward in assessing PROTAC molecules and optimising their properties. As we make this groundbreaking technology available, we invite our clients to explore the possibilities it presents in enhancing their drug discovery efforts. The ChameLogK assay, now a part of our service portfolio, positions our company at the forefront of innovation, providing clients with a valuable tool to navigate the complexities of molecule design in the ever-evolving landscape of drug development

Integrin Assay

Decoding cellular interactions

Integrins are heterodimeric cell surface receptors and are key regulators affecting cell morphology, proliferation, survival and differentiation. Mutations in specific integrins or deregulated expressions are associated with a variety of diseases. Each integrin consists of α-subunit and a β-subunit, of which there are 18 and 8 variants, respectively, creating 24 known heterodimers. Integrins act as adhesion receptors with the unusual ability to signal in both directions across the plasma membrane. Integrins can therefore enable human cells to respond to changes in the extracellular environment (via outside-in signalling) and can influence the extracellular environment (via inside-out signalling). We have successfully established biochemical and cell-based assays to assess target engagement of small molecules for different integrin targets.

FLIPR Penta Technology

Collaborative FLIPR assay services for drug discovery programs o2h discovery’s commitment to excellence in scientific research is exemplified by our recent investment in the FLIPR Penta technology. We stand ready to collaborate seeking FLIPR-based assay services for different drug discovery programs. The introduction of the FLIPR Penta High- Throughput Cellular Screening System to our repertoire, enables rapid screening of compound libraries and to assess the effects of potential drug candidates in a fast, automated, and precise manner. It has extensive use in understanding

GPCR and ion channel biology. With the simultaneous pipette and read function, plus high-end camera system, we can allow up to 100 measurements per second and provide detailed information about cardiomyocyte and/or neuronal oscillations.

We offer multiple fluorescence or luminescence-based assay readouts, and can support in measuring calcium flux, potassium and membrane potential.

Psychedelics Research

A new frontier in mental health research

At o2h, we have developed and screened a series of 5-HT2A-small molecules with varying potencies towards Gq and β-arrestin-biased signaling thererby shedding light on the dynamics associated with the 5-HT2A receptor. These serve as invaluable tools in elucidating the specific intracellular responses providing comprehensive understanding for drug discovery and pharmacological research.

Our scientists can support in identifying compounds with differential signaling activities, downstream of the 5-HT receptor, stimulated via Gαq and betaarrestin pathways.

o2h can also support in exploratory studies using BRET-based protein-protein interactions and complementation assays (an area that is currently gaining interest).

High-Content Imaging

A transformative approach to drug discovery

At o2h discovery, our high-content imaging assays are designed to address a broad spectrum of biological questions, including protein trafficking, translocation, receptor internalisation, and target recruitment to specific organelles. These assays offer critical insights into molecular interactions and sub-cellular processes, enabling a deeper understanding of cellular dynamics.

Our expertise also spans cell cycle analysis, where we investigate mitotic progression, cytokinesis, and the effects of DNA Damage Response (DDR) mechanisms. By integrating assessments of proliferation, apoptosis, and autophagy, we provide a comprehensive view of cellular stress responses and overall cellular health. Additionally, we specialise in identifying phenotypic and morphological changes that signal invasiveness, drug resistance, and other disease-relevant behaviours, offering valuable insights for therapeutic development.

Surface Plasmon Resonance

A highly experienced team with a track record of delivering Project-tailored SPR solutions o2h discovery offers a broad gamut of biochemical, biophysical, and cell-based bioassay screening services for supporting drug discovery programs of our various collaborators. To augment these services, we have incorporated SPR-based assays (surface plasmon resonance) in our portfolio using state-of-the-art Biacore T200 system. The Biacore T200 provides real-time, label-free, affinity and kinetic analysis for various types of biomolecular interactions with high sensitivity and accuracy. This system enables our team to deliver robust, high-quality data in a timebound manner for the screening of small molecules, biologics and NBEs (novel biological entities) at any phase of drug development. We offer various projecttailored SPR solutions which include the following: Fragment-based drug discovery (FBDD) Small molecule drug discovery Biotherapeutic drug discovery

ChameLogK: A Rapid, High-Throughput Assay to AssessChameLogK: A Rapid, High Throughput Assay to Assess Bioavailability of Beyond Rule of Five CompoundsBioavailability of Beyond Rule of Five Compounds

• 1 2p. 1
• 2 1p. 22
• 1,2p. 2

1,2 e StaceCatherine StaceDharmesh BhattDharmesh Bhatt, Andy Morley , Claudio Dagostin, Andy Morley , Claudio Dagostin, Mayank Gupta , Pranav Pandya, Mayank Gupta , Hardic Dave, Pranav Pandya, Dhruv Lad, Hardic Dave, Vinkal Zalavadia, Dhruv Lad , Vinkal Zalavadia, Vishal Patel , Hemal Soni, Vishal Patel, Nilesh Dagia, Hemal Soni, Sunil Shah, Nilesh Dagia, Prashant Shah, Sunil Shah , Prashant Shah

overy Pvt. Ltd., Changodar, Ahmedabad, India.o2h Discovery Pvt. Ltd., Changodar, Ahmedabad, India.o2h Ltd., Mill SciTech Park, Hauxton, Cambridgeshire, UK.o2h Ltd., Mill SciTech Park, Hauxton, Cambridgeshire, UK.* Correspondence to [email protected]* Correspondence to [email protected] act Abstract

LogKChameLogK is a cutting-edge method for measuring chameleonicity, a vital factor in assessing cell permeability propensity of small molecules, includingis a cutting edge method for measuring chameleonicity, a vital factor in assessing cell permeability propensity of small molecules, including d Rule‘Beyondof Five’Rule-of-such asFive’PROTACs,such as PROTACs, macrocycles and peptides. Chameleonicity is ability of molecules to conformationally adapt to their environment,macrocycles and peptides Chameleonicity is ability of molecules to conformationally adapt to their environment, IAM

IAM by intramoleculardriven by intramolecular hydrogen bonds; ChameLogK combines lipophilicity (BRlogD) and polarityhydrogen bonds ChameLogK combines lipophilicity (BRlogD) and polarity (Δlog kw

(Δdescriptorslog kw

) descriptors. Leveraging literature methods,Leveraging literature methods, s developedo2h has developed a reliable, high-throughput platform to rapidly and inexpensively measure chameleonicity, accelerating optimization of Beyond Rule-of-a reliable, high throughput platform to rapidly and inexpensively measure chameleonicity, accelerating optimization of Beyond Rule of erapeuticFive therapeutic compoundscompounds meleonicity: An indicator of bioavailability and cellChameleonicity: An indicator of bioavailability and cell

Assay Validation and Platform DevelopmentAssay Validation and Platform Development permeability for Beyond Rule of Five moleculespermeability for Beyond Rule of Five molecules o2h conducted a rigorous validation process, with a variety of different chemicalo2h conducted a rigorous validation process, with a variety of different chemical eleonicity is the capacity of aChameleonicity is the capacity of a ule to hide polarity in nonmolecule to hide polarity in non-polarpolar nments and expose it in water,environments and expose it in water, chieving sufficient permeabilityhelp achieving sufficient permeability olubility for drug molecules withand solubility for drug molecules with olecular weight [1]high molecular weight [1]

species, underscoring the reliability of the assay as a robust and transferable platform,species, underscoring the reliability of the assay as a robust and transferable platform, broadly applicable for multiple drug discovery programs.broadly applicable for multiple drug discovery programs.

Validated with >20 different compounds, including macrocycles, nonValidated with >20 different compounds, including macrocycles, non-macrocyclicmacrocyclic compounds, and PROTACscompounds, and PROTACs >100 compounds examined to date confirm versatility and effectiveness in designing>100 compounds examined to date confirm versatility and effectiveness in designing bioavailable compounds beyond Ro5 constraintsbioavailable compounds beyond Ro5 constraints

Adapted from DanielusAdapted from Danieluset al, Nature 2020 [2] et al, Nature 2020 [2]

A any years, it has been known that bRo5 molecules, such as macrocycles and smallFor many years, it has been known that bRo5 molecules, such as macrocycles and small

B es, can exhibit chameleonic propertiespeptides, can exhibit chameleonic propertiesconformational flexibilityconformational flexibility - driven by thedriven by the tion of intramolecular hydrogen bondsformation of intramolecular hydrogen bonds [3][3]

ompounds often suffer from a poor permeability and bioavailability profile.bRo5 compounds often suffer from a poor permeability and bioavailability profile. sign and optimization of compounds with chameleonicThe design and optimization of compounds with chameleonic rties is central toproperties is central to optimizing solubility and permeability [4]optimizing solubility and permeability [4]

IAM

IAM

D, Δlog kBRlogD, Δw and ChameLogK are threelog kw and ChameLogK are three ementary measures revealing lipophilicity,complementary measures revealing lipophilicity, lity, exposed polarity, and chameleonic masking;solubility, exposed polarity, and chameleonic masking; er forming a triad of drugtogether forming a triad of drug-likeness, guidinglikeness, guiding er compound prioritization by explainingsmarter compound prioritization by explaining ability and bioavailability [5]permeability and bioavailability [5]

Figure 1: A. Output data showing correlation of Log K’ with % acetonitrile for a PROTAC andFigure 1: A. Output data showing correlation of Log K’ with % acetonitrile for a PROTAC and a classic Ro5 compound;a classic Ro5 compound;B. Summary of chameleonicity across a range of chemical speciesB. Summary of chameleonicity across a range of chemical species o2h has streamlinedo2h has streamlined

Results

Results processes for processes for PROTACs: Displayed distinct “Chameleonic” qualities.PROTACs: Displayed distinct “Chameleonic” qualities.maximal throughputmaximal throughput establishedOther established phys chem measures relating to permeability, such as ePSA [6][1] arephys chem measures relating to permeability, such as ePSA [6][1] are aratively low throughput and costly, revealing a need for an easilycomparatively low throughput and costly, revealing a need for an easily-accessibleaccessible and productivityand productivity

Non macrocyclesNon-macrocycles: Moderate chameleonicity, showingModerate chameleonicity, showing ative measure to support rapid design and optimization of bRo5 compoundsalternative measure to support rapid design and optimization of bRo5 compounds expected flexibility compared to classic Ro5 and PROTACsexpected flexibility compared to classic Ro5 and PROTACscreating a cost-creating a cost- Macrocycles: Led by Cyclosporin, showed variable behaviourMacrocycles: Led by Cyclosporin, showed variable behavioureffective and easy-effective and easy- [5] and hasE3 Ligands: Consistent behaviour, possibly involving internalE3 Ligands: Consistent behaviour, possibly involving internalaccess version of thisaccess version of this ameLogK method was pioneered in byThe ChameLogK method was pioneered in by GiuliaGiulia Caron’s group in TurinCaron’s group in Turin[5] and has ground breakingground-breaking folding or interactionsfolding or interactions red significant interest in the academic settinggarnered significant interest in the academic setting, but had not been developed into, but had not been developed into technique

Ro5 moleculesRo5 molecules like caffeine, and diazepam defied expectationlike caffeine, and diazepam defied expectation technique transferable platform for routine screening in the commercial settinga fully-transferable platform for routine screening in the commercial setting scovery is the first in the world to offer the ChameLogK assay to clients too2h discovery is the first in the world to offer the ChameLogK assay to clients to rt their drug discovery programssupport their drug discovery programs

Supporting a range of modalitiesSupporting a range of modalities

Measuring ChameLogK: How it worksMeasuring ChameLogK: How it works

The increasing need to explore the bRo5 spaceThe increasing need to explore the bRo5 spaceto access novel chemistry, betterto access novel chemistry, better mechanisms of action, and exciting new modalities, requires a way to quickly andmechanisms of action, and exciting new modalities, requires a way to quickly and inexpensively measure chameleonicityinexpensively measure chameleonicity

LogK is the difference (ChameLogK is the difference (Δlog k′) between theΔlog k′) between the ental retention at 100%experimental retention at 100% MeCN on a PLRP-SMeCN on a PLRP S , and the extrapolated retention at 100%column, and the extrapolated retention at 100% MeCNMeCN d from the linear region measured atobtained from the linear region measured at 0% MeCN50/60/70% MeCN. Positive values indicate extra. Positive values indicate extra on in the nonretention in the non-polar limit, consistent withpolar limit, consistent with masking/folding (i.e. chameleonicity).polarity masking/folding (i.e. chameleonicity).

d features:Method features: based method, using PLRPHPLC-based method, using PLRP-S columnS column rd the retention time (RT) of compound inRecord the retention time (RT) of compound in ring ratios ofdiffering ratios of water:acetonitrilewater:acetonitrile r regression to fit of Log k' PLRPLinear regression to fit of Log k' PLRP-S and the %S and the % nitrile; Chameleonic properties are observedacetonitrile; Chameleonic properties are observed teeper downward slope with an upas a steeper downward slope with an up-ticktick polate to calculate at 100% acetonitrile andExtrapolate to calculate at 100% acetonitrile and late Chamelogkcalculate Chamelogk using the formula:using the formula: melogk = Exp. log k' 100Chamelogk = Exp. log k' 100 - Ext. log k' 100Ext. log k' 100

This assay represents aThis assay represents asignificant step forwardsignificant step forwardin assessing molecules such asin assessing molecules such as PROTACs and optimization of their properties [7] Enabling:PROTACs and optimization of their properties [7] Enabling:

Hetero bifunctionals

Glues

Optimization to fit with target biology; e.g. crossingOptimization to fit with target biology; e.g. crossing

Heterothe BBB or efficiently accessingthe BBB or efficiently accessingintracellular targetsintracellular targetsPeptides bifunctionals

Characterization of molecules to guideCharacterization of molecules to guidedesign and design and create a robust pre-clinical data packagecreate a robust pre-clinical data package Understand theGlues

Understand therelationship between biophysicalrelationship between biophysicalMacrocycles and cell-basedand cell-basedresults results

Peptides

Macrocycles

A key part of your drug discovery programA key part of your drug discovery program o2h offers the o2h offers the ChameLogK assay as partChameLogK assay as part of a comprehensive suite of ADMET andof a comprehensive suite of ADMET and assay biology, eassay biology, enabling fullnabling full characterisation of compoundscharacterisation of compounds

Graphics adapted from [2] and [5]Graphics adapted from [2] and [5]

o2h also offers a range of integratedo2h also offers a range of integrated services linking directly to this field:services linking directly to this field:

ReferencesReferences l (2021) ‘Prediction of Chameleonic Efficiency’,[1] David et al (2021) ‘Prediction of Chameleonic Efficiency’,ChemMedChem 16(7), pp2669ChemMedChem 16(7), pp2669-26852685 et al, (2020) ‘[2] Danielas et al, (2020) ‘Solution Conformations Explain the ChameleonicSolution Conformations Explain the Chameleonic BehaviourBehaviour of Macrocyclic Drugs’,of Macrocyclic Drugs’,Nature 26(23), pp5231Nature5244 26(23), pp5231-5244 nd Lokey, (2017) ‘Chapter 5:[3] Bockus and Lokey, (2017) ‘Chapter 5:Bioactive and MembraneBioactive and Membrane-Permeable Cyclic Peptide Natural Products’,Permeable Cyclic Peptide Natural Products’,Practical Medicinal Practical Medicinal ith Macrocycles: Design, Synthesis, and Case Studies,Chemistry with Macrocycles: Design, Synthesis, and Case Studies,John Wiley and Sons, Inc.John Wiley and Sons, Inc. et al, (2023), ‘Cell[4] Ramelotpermeable chameleonic peptides: Exploiting conformational dynamics in de novo cyclic peptide design,et al, (2023), ‘Cell-permeable chameleonic peptides: Exploiting conformational dynamics in de novo cyclic peptide design, ion in Structural Biology 80, p102603Current Opinion in Structural Biology 80, p102603 enez et al (2023), ‘[5] Garcia Jimenez et al (2023), ‘Chamelogk: A ChromatographicChamelogk: A Chromatographic Chameleonicity Quantifier to Design Orally Bioavailable Beyond-Rule-Chameleonicity Quantifier to Design Orally Bioavailable Beyond Rule ournal of Medicinal Chemistry 66(15), p10681.of-5 Drugs’, Journal of Medicinal Chemistry 66(15), p10681.Seminal article by Giulia Caron’s groupSeminal article by Giulia Caron’s group al (2014), ‘EPSA: A Novel Supercritical Fluid Chromatography Technique Enabling the Design of Permeable Cyclic Peptides’,[6] Goetz et al (2014), ‘EPSA: A Novel Supercritical Fluid Chromatography Technique Enabling the Design of Permeable Cyclic Peptides’, al Chemistry Letters, 5(10).ACS Medicinal Chemistry Letters, 5(10). t al (2024), ‘Exploring the chemical space of orally bioavailable PROTACs’, Drug Discovery Today 29(4), p103917.[7] Apprato et al (2024), ‘Exploring the chemical space of orally bioavailable PROTACs’, Drug Discovery Today 29(4), p103917.

PROTACs: off PROTACs:the shelf toolbox, featuring >100 buildingoff-the-shelf-toolbox, featuring >100 building blocks, a range of E3 ligands and readyblocks, a range of E3 ligands and ready-to-use linkersto use linkers Custom Peptide SynthesisCustom Peptide Synthesis: parallel and solid & solution: parallel and solid & solution phase; ‘peptide guarantee’phase; ‘peptide guarantee’ Macrocycles and natural product chemistryMacrocycles and natural product chemistry Molecular gluesMolecular glues, with comprehensive assay suite for in, with comprehensive assay suite for incell target engagement and degradationcell target engagement and degradation Medicinal and syntheticMedicinal and syntheticchemistry chemistry nt to learn more about this assayWant to learn more about this assay

Scan the QR code toScan the QR code to how o2h supports integratedand how o2h supports integrated explore our website:explore our website:

g discovery programs…?drug discovery programs…?

Read our blogRead our blog on ChameLogK:on ChameLogK:

Scan the QR to read moreScan the QR to read more about our biology matchabout our biology match

• Contact us:
• Contact us:
• funding opportunitiesfunding opportunities [email protected]@o2h.com

High-content analysis of DNA damage markers in multiplexed cell lines using the SemaCyte microcarrier platform

Jackline Agwenge, Simon Stockwell o2h Discovery, Hauxton House, Mill SciTech Park, Cambridge CB22 5HX

Abstract High-content imaging (HCI) offers a considerable depth of analysis options when considering the requirements for developing a new cellular assay. The information-rich image data collected during an HCI assay allows access to measures of spatial, quantitative, temporal and morphological markers of target engagement, often requiring monolayers of adherent cells seeded to assay plates. The SemaCyte microcarrier system developed by Semarion enables powerful new strategies to manage cell monolayers in drug discovery workflows. In collaboration with Semarion, o2h Discovery have updated an established HCI approach to DNA damage to explore

SemaCyte-enabled enhancements in cellular assays; miniaturisation of seeding, assay-ready adherent cells, multiplexed cell lines and subpopulation barcoding are investigated here. Objectives Perform a first-pass test using the SemaCyte system to obtain and analyse cellular HCI data, making use of cell multiplexing capabilities and same-day set up of assays from frozen cell SemaCyte stocks

Assay details o 96-well plate, 2hr, 11-point etoposide (EP) DRC o Cells presented as pooled SemaCytes in each well o Using frozen SemaCytes on same day as recovery o Fixed endpoint - probes for DNA damage markers o 3 multiplexed cell lines per well – U2OS, A549, U87MG o 4 SemaCyte barcodes used for deconvolution by HCI th o Plate reference control: U2OS cell line re-used for 4 barcode providing fixed 50μM set, spiked to every well

Key findings & next steps Multiplexing

Early analyses with this data set yield sufficient information to characterise and differentiate variability in DNA damage dose responses between cell lines grown in parallel using SemaCytes

Thawed monolayers recovery of frozen assay-ready monolayers worked well (>= 75% viable) and offers a new flexibility to scheduling deployment to assays and maintaining cells for Data handling

The ability to deconvolute mixed populations using image processing to sort SemaCytes by barcodes proved accessible and opens further options for how to organize and control HCI assays

Next steps – A deeper dive into the current data set is planned, including exploration of RAD51 and implementation of dynamic image acquisition strategies such as the CellInsight EurekaScan

Workflow 1. Cell handling

3 cell lines: o U2OS o U87MG o A549 Each assigned SemaCyte barcodes Revived following frozen storage Pooled for assay Drugged 2hr with EP DRC same day Fixed and stained for subsequent HCI

2. High-content imaging

Hoeschst 33342 αα RAD51 (AF488)RAD51 (AF488)

10x objective 25 fields per channel Image stitching α γH2AX (AF647)

Phalloidin (iFluor555)

Barcodes (BF)

ThermoFisher Scientific CX7 CellInsight LED Pro

3. Image processing I – deconvolution QC and extraction of SemaCytes according to cell line-specific barcodes

Barcoded cell line groups per well

4. Image processing II – quantitation Cell Profiler to detect and characterise cells within SemaCyte-defined image masks

Cell by cell feature extraction

Cell line-specific etoposide dose response curves

Acknowledgements o2h Discovery would like to acknowledge the team at Semarion for their collaborative support and insight. Furthermore, ThermoFisher Scientific have provided indispensable support across instrument and data-handling steps in the workflow.

First-pass analysis focused on γH2AX marker of DNA damage Data resolves rank order cell line sensitivities to EP Separately barcoded technical control U2OS 50μM EP population correctly intersect main DRC

Poster No - ProUPS_080Poster No - ProUPS_080

Integrated drug discovery services from o2h: AdvancingIntegrated drug discovery services from o2h: Advancing therapeutic innovation through collaborative researchtherapeutic innovation through collaborative research

Romit BoseRomit Bose, Prasad Sulkshane, Rajesh Yesodharan, Animesh Pandit, Anagha Dahake, Prachi Soni, Priya Gajjar, Adit Kotak, Simon Stockwell
, Keith Woodley
, Christian Mutti
, Jackline Agwenge
,, Prasad Sulkshane, Rajesh Yesodharan, Animesh Pandit, Anagha Dahake, Prachi Soni, Priya Gajjar, Adit Kotak, Simon Stockwell
, Keith Woodley
, Christian Mutti
, Jackline Agwenge
, Alice Willer
, Sunil ShahAlice Willer
, Sunil Shah
, Prashant Shah
, Prashant Shah, Gayathri Sadasivam, Gayathri Sadasivam

 In vitro Biology, o2h Discovery Pvt. Ltd., Changodar, Ahmedabad, India In vitro Biology, o2h Discovery Pvt. Ltd., Changodar, Ahmedabad, India  In vitro Biology, o2h Discovery Pvt. Ltd., Mill SciTech Park, Hauxton, Cambridgeshire, UK In vitro Biology, o2h Discovery Pvt. Ltd., Mill SciTech Park, Hauxton, Cambridgeshire, UK *Correspondence to [email protected]*Correspondence to [email protected]

OverviewOverview o2h Discovery has enhanced its biology expertise across therapeutic areas in Cambridge, UK, and Ahmedabad, India, utilizing advanced platforms to support all stages of preclinical drugo2h Discovery has enhanced its biology expertise across therapeutic areas in Cambridge, UK, and Ahmedabad, India, utilizing advanced platforms to support all stages of preclinical drug discovery, from lead optimization to IND filing. Our Integrated Drug Discovery (IDD) approach combines biology, chemistry, and ADME capabilities to accelerate the design-make-test-analyzediscovery, from lead optimization to IND filing. Our Integrated Drug Discovery (IDD) approach combines biology, chemistry, and ADME capabilities to accelerate the design-make-test-analyze cycles. Our experienced biologists develop customizable assays to support potency-to-efficacy translation and mechanism-of-action characterization, with seamless collaboration between ourcycles. Our experienced biologists develop customizable assays to support potency-to-efficacy translation and mechanism-of-action characterization, with seamless collaboration between our UK and India teams. Specializing in small molecule drug discovery, we bring in-depth expertise in target biology, providing valuable insights that drive progress in complex biology projects acrossUK and India teams. Specializing in small molecule drug discovery, we bring in-depth expertise in target biology, providing valuable insights that drive progress in complex biology projects across a broad range of therapeutic areas.a broad range of therapeutic areas.

High-content imaging (HCI)High-content imaging (HCI)

Integrated Drug Discovery (IDD)Integrated Drug Discovery (IDD)

Integrin BiologyIntegrin Biology o2h Discovery leverages high-content imaging (HCI) systemso2h Discovery leverages high-content imaging (HCI) systemso2h offers a comprehensive suite of R&D services to propel youro2h offers a comprehensive suite of R&D services to propel your Customizable platform to evaluate compoundCustomizable platform to evaluate compound with confocal capabilities for high-resolution, quantitative,with confocal capabilities for high-resolution, quantitative, drug discovery program from target validation to INDdrug discovery program from target validation to IND potency and specificity in cell adhesion assayspotency and specificity in cell adhesion assays realtime analysis of lead molecule characterization acrossrealtime analysis of lead molecule characterization across submission.submission.

• targeting multiple integrins.targeting multiple integrins.
• several biological processes.several biological processes.
• Comprehensive Toolbox:Comprehensive Toolbox:In-house In-house

Scan the QR toScan the QR to Our assays investigate the inhibition or activationOur assays investigate the inhibition or activation expertise in chemistry, biology, ADME withexpertise in chemistry, biology, ADME withread more aboutread more about

These include protein trafficking, receptor internalization, cellThese include protein trafficking, receptor internalization, cell of integrin pairs—key drug targets for numerousof integrin pairs—key drug targets for numerous our IDD servicesour IDD services advanced capabilities in SPR, and HCI.advanced capabilities in SPR, and HCI.

cycle progression, apoptosis, drug resistance, DNA damagecycle progression, apoptosis, drug resistance, DNA damage diseases. diseases.

response, and changes in cell health and morphology.response, and changes in cell health and morphology.

By providing spatial, quantitative, and morphological data,By providing spatial, quantitative, and morphological data, HCI enables precise target engagement analysis.HCI enables precise target engagement analysis.

Therapeutic Foresight:Therapeutic Foresight:Specializing inSpecializing in cancer biology, immuno-oncology,cancer biology, immuno-oncology, metabolic disorders, and CNS diseases.metabolic disorders, and CNS diseases.

Our custom cell lines enable precise evaluationOur custom cell lines enable precise evaluation of differential inhibition across integrin pairs,of differential inhibition across integrin pairs, simplifying specificity testing.simplifying specificity testing.

o2h has developed bespoke HCI speckle assay to analyzeo2h has developed bespoke HCI speckle assay to analyze phenotypic changes in spliceosome factors induced byphenotypic changes in spliceosome factors induced by molecules targeting mRNA splicing factors.molecules targeting mRNA splicing factors.

In collaboration with Semarion, o2h Discovery has enhancedIn collaboration with Semarion, o2h Discovery has enhanced the HCI approach for DNA damage analysis using thethe HCI approach for DNA damage analysis using the innovative SemaCyteinnovative SemaCytemicrocarrier system, optimizing cellmicrocarrier system, optimizing cell monolayer management for more efficient drug discovery.monolayer management for more efficient drug discovery.

In-depth compound characterization through otherIn-depth compound characterization through other bespoke cellular assays using flow cytometry andbespoke cellular assays using flow cytometry and HCI, assessing activity in biological settings.HCI, assessing activity in biological settings.

Scan the QR toScan the QR to read more aboutread more about our integrin our integrin biology servicesbiology services

Nuclear protein translocation phenotypeNuclear protein translocation phenotype

Assay ParametersAssay Parameters

3 cell lines (U2OS, U87MG, A549)3 cell lines (U2OS, U87MG, A549) Each assigned SemaCyte barcodesEach assigned SemaCyte barcodes Revived following frozen storageRevived following frozen storage Pooled for assay Pooled for assay Drugged 2hr with EP DRC same dayDrugged 2hr with EP DRC same day Fixed and stained for subsequent HCICFixed and stained for subsequent HCIC

Experimental WorkflowExperimental Workflow

1. Cell line handling1. Cell line handling 2. High-content imaging2. High-content imaging 3. Image processing I – deconvolution3. Image processing I – deconvolution 4. Image processing II – quantitation4. Image processing II – quantitation

Cell line-specific etoposideCell line-specific etoposide dose response curvesdose response curves

Psychedelics DiscoveryPsychedelics Discovery ServicesServices

At o2h, we have developed and screened a series ofAt o2h, we have developed and screened a series of 5-HT2A small molecules with varying potencies5-HT2A small molecules with varying potencies towards Gq andtowards Gq andβ-arrestin-biased signalling,β-arrestin-biased signalling, providing insights into 5-HT2A receptor dynamics.providing insights into 5-HT2A receptor dynamics.

These molecules serve as key tools forThese molecules serve as key tools for understanding specific intracellular responses,understanding specific intracellular responses, advancing drug discovery research.advancing drug discovery research.

• GPCR SignallingGPCR Signalling
• Calcium ReleaseCalcium Release
• (https://doi.org/10.3389/fcell.2021.611443)(https://doi.org/10.3389/fcell.2021.611443)

5-HT2A Receptor Agonist-Induced Calcium Release5-HT2A Receptor Agonist-Induced Calcium Release

IP1 accumulationIP1 accumulation β-arrestin recruitmentβ-arrestin recruitment

Scan the QR to readScan the QR to read more about ourmore about our HCI assay servicesHCI assay services

Immuno-oncology (IO)Immuno-oncology (IO)

o2h offers various IO research services for theo2h offers various IO research services for the phenotypic screening of novel immunephenotypic screening of novel immune therapeutics, which includes the following:therapeutics, which includes the following:

PBMC isolation and immunophenotypingPBMC isolation and immunophenotyping

Receptor expression using FACSReceptor expression using FACS

Co-culture of cancer cells with immune cellsCo-culture of cancer cells with immune cells

Cytotoxicity of immunotherapeuticCytotoxicity of immunotherapeutic (CFSE/7-AAD)(CFSE/7-AAD)

Scan the QR toScan the QR to read more aboutread more about our IO Servicesour IO Services

Mitochondrial BiologyMitochondrial Biology o2h offers cutting-edge assays that detect and monitor hanges ino2h offers cutting-edge assays that detect and monitor hanges in mitochondrial structure and function, helping researchers unravelmitochondrial structure and function, helping researchers unravel the intricacies of these organelles and their impact on cellularthe intricacies of these organelles and their impact on cellular health. Dysfunctional mitochondria are implicated in diseaseshealth. Dysfunctional mitochondria are implicated in diseases such as Parkinson’s, Alzheimer’s, diabetes, and even aging.such as Parkinson’s, Alzheimer’s, diabetes, and even aging.

Assay ServicesAssay Services

Mitochondrial ROSMitochondrial ROS

Scan the QR to read moreScan the QR to read more about our psychedelicabout our psychedelic discovery servicesdiscovery services

Superoxide production usingSuperoxide production using MitoSOX red dye – flow cytometryMitoSOX red dye – flow cytometry Mitochondrial Biogenesis orMitochondrial Biogenesis or Degradation (Mitophagy) – HCIDegradation (Mitophagy) – HCI Mitochondrial Calcium uptake usingMitochondrial Calcium uptake using RHOD-2 AM dye – FLIPRRHOD-2 AM dye – FLIPR Jess-Based Western Blotting of proteinsJess-Based Western Blotting of proteins (SDHA, MFN2) involved in mitochondrial(SDHA, MFN2) involved in mitochondrial fission, fusion, and apoptosisfission, fusion, and apoptosis

State-of-the-art EquipmentState-of-the-art Equipment

Our cutting-edge facilities are equipped withOur cutting-edge facilities are equipped with advanced instruments to ensure precision andadvanced instruments to ensure precision and efficiency in biology research.efficiency in biology research.

Mitochondrial BiogenesisMitochondrial Biogenesis JESS Western JESS WesternMitochondrial CalciumMitochondrial Calcium HCI assay

• HCI assay
• Blotting
• Blotting flux flux
• Biacore T200

Biacore T200CellInsight CX7 HCSCellInsight CX7 HCSFLIPR Penta

• FLIPR Penta
• CytoFLEX S
• CytoFLEX S
• JESS
• JESS
• IncuCyte S3

IncuCyte S3

Scan the QRScan the QR to know moreto know more o2h Biology Match Funding Awardo2h Biology Match Funding Award

From idea to milestone, start generating data on the benchFrom idea to milestone, start generating data on the bench Match Funding ofMatch Funding ofHighly ExperiencedHighly ExperiencedComprehensiveComprehensiveAccess to Cutting-edgeAccess to Cutting-edge up to 50% up to 50%

Biologists Biologists Project ManagementProject ManagementEquipment SuiteEquipment Suite

Poster No - ProUPS_079Poster No - ProUPS_079

An array of Targeted Degradation approaches offered as a partAn array of Targeted Degradation approaches offered as a part of integrated drug discovery services by o2h Discoveryof integrated drug discovery services by o2h Discovery

Prasad SulkshanePrasad Sulkshane, Romit Bose›, Keith Woodleyœ, Alice Willerœ, Shubham Gourana›, Anagha Dahake›, Animesh Pandit›, Jackline Agwengeœ, Christian Muttiœ, Simon Stockwellœ, Rajesh Yesodharan›,, Romit Bose›, Keith Woodleyœ, Alice Willerœ, Shubham Gourana›, Anagha Dahake›, Animesh Pandit›, Jackline Agwengeœ, Christian Muttiœ, Simon Stockwellœ, Rajesh Yesodharan›, Sunil ShahSunil Shah, Prashant Shah, Prashant Shahand Gayathri Sadasivamand Gayathri Sadasivam

 In vitro Biology, o2h Discovery Pvt. Ltd., Changodar, Ahmedabad, India In vitro Biology, o2h Discovery Pvt. Ltd., Changodar, Ahmedabad, India  In vitro Biology, o2h Discovery Pvt. Ltd., Mill SciTech Park, Hauxton, Cambridgeshire, UK In vitro Biology, o2h Discovery Pvt. Ltd., Mill SciTech Park, Hauxton, Cambridgeshire, UK *Correspondence to [email protected]*Correspondence to [email protected] o2h Discoveryo2h Discovery o2h Discovery provides early-stage drug discovery services from its advanced facilities in Ahmedabad, India, and Cambridge, UK.o2h Discovery provides early-stage drug discovery services from its advanced facilities in Ahmedabad, India, and Cambridge, UK. The company has expanded its expertise in targeted protein degradation (TPD), offering a comprehensive suite of solutions for PROTAC design, synthesis, screening, and a customizable "off-the-shelf"The company has expanded its expertise in targeted protein degradation (TPD), offering a comprehensive suite of solutions for PROTAC design, synthesis, screening, and a customizable "off-the-shelf" PROTAC toolbox. Our experienced biology team provides assays for binary and ternary complex formation, protein degradation, and DC50 estimation, ensuring fully integrated capabilities.PROTAC toolbox. Our experienced biology team provides assays for binary and ternary complex formation, protein degradation, and DC50 estimation, ensuring fully integrated capabilities. Leveraging expertise in small molecule discovery and bespoke assay development, o2h enables screening of small molecules that bind to unique RNA folds.Leveraging expertise in small molecule discovery and bespoke assay development, o2h enables screening of small molecules that bind to unique RNA folds. Drawing on insights from Tong et al. (2023), o2h Discovery is applying these findings to design RNA-targeting molecules. By conjugating RNA-binding small molecules with RNase L-recruitingDrawing on insights from Tong et al. (2023), o2h Discovery is applying these findings to design RNA-targeting molecules. By conjugating RNA-binding small molecules with RNase L-recruiting agents, or RIBOTACs, o2h aims to develop novel RNA degraders using a PROTAC-like approach, enhancing RNA-targeted drug discovery.agents, or RIBOTACs, o2h aims to develop novel RNA degraders using a PROTAC-like approach, enhancing RNA-targeted drug discovery. Looking ahead, o2h is also exploring the use of DUBTACs for protein stabilization and other TAC-based mechanisms to clear protein aggregates, broadening its scope in targeted degradationLooking ahead, o2h is also exploring the use of DUBTACs for protein stabilization and other TAC-based mechanisms to clear protein aggregates, broadening its scope in targeted degradation strategies.strategies.

PROTAC (PROteolysis TArgeting Chimera)PROTAC (PROteolysis TArgeting Chimera)

RiboTAC (RNA-TArgeting Chimera)RiboTAC (RNA-TArgeting Chimera)

Degrader designDegrader design

Constructed to bind both targetConstructed to bind both target and E3 ligase through a crosslinkerand E3 ligase through a crosslinker

Ternary complexTernary complex

Degrader recruits target to E3 ligaseDegrader recruits target to E3 ligase

Specific questions:Specific questions:

Current RNA-targeting modalities have been limited to antisense oligonucleotides, which mediateCurrent RNA-targeting modalities have been limited to antisense oligonucleotides, which mediate Ribonuclease-dependent RNA cleavage.Ribonuclease-dependent RNA cleavage.

Q. Is my target degraded?Q. Is my target degraded?

However, RNA is remarkably structured and intricately folded as hairpin loops through itsHowever, RNA is remarkably structured and intricately folded as hairpin loops through its Q. What is the binary affinity for POI & E3 ligase?Q. What is the binary affinity for POI & E3 ligase?intramolecular base pairing, forming a series of unique secondary structures.intramolecular base pairing, forming a series of unique secondary structures. Q. Do they form ternary complex?Q. Do they form ternary complex? Q. Is my target ubiquitinated?Q. Is my target ubiquitinated?

These RNA folds, similar to motifs or domains in proteins, may offer a unique opportunityThese RNA folds, similar to motifs or domains in proteins, may offer a unique opportunity for targeting by small molecules through specific binding.for targeting by small molecules through specific binding.

PolyubiquitinationPolyubiquitination

Ubiquitin (Ub) added to target’sUbiquitin (Ub) added to target’s Lys residues

Lys residues

Target degradationTarget degradation

Ub-marked target is degradedUb-marked target is degraded by the proteasomeby the proteasome

Case Study:Case Study: Target protein:Target protein:BD2 domain of BRD4BD2 domain of BRD4 E3 Ubiquitin ligase:E3 Ubiquitin ligase:VHL

• VHL
• PROTAC molecule:PROTAC molecule:MZ1
• MZ1

The biological outcome of such RNA binding small molecules can be further enhanced byThe biological outcome of such RNA binding small molecules can be further enhanced by appending a functional group to it, which can recruit a Ribonuclease, activate it and cleaveappending a functional group to it, which can recruit a Ribonuclease, activate it and cleave the target RNA.the target RNA.

We have developed SPR & Fluorescence Dye Displacement assays as robust and highlyWe have developed SPR & Fluorescence Dye Displacement assays as robust and highly sensitive methods to study these specific RNA-small molecule interactions.sensitive methods to study these specific RNA-small molecule interactions.

Case StudyCase Study

Demonstration of ternary complex formation & target protein degradation byDemonstration of ternary complex formation & target protein degradation by Nanoluciferase assay:Nanoluciferase assay:

Studying the specific interactions between c-Jun mRNA and a small moleculeStudying the specific interactions between c-Jun mRNA and a small molecule [Ref. Tong et al. (2023)].[Ref. Tong et al. (2023)].

A specific part of c-Jun mRNA bearing a unique loop/kink – Wild Type (WT), where aA specific part of c-Jun mRNA bearing a unique loop/kink – Wild Type (WT), where a HEK293 cells expressing NanoLuc-BRD4 (Donor) and Halo-Tag-VHL (acceptor) at 1:100 ratio.HEK293 cells expressing NanoLuc-BRD4 (Donor) and Halo-Tag-VHL (acceptor) at 1:100 ratio.small molecule – c-Jun mRNA binder binds.small molecule – c-Jun mRNA binder binds.

Ternary Complex FormationTernary Complex Formation

Target Protein DegradationTarget Protein Degradation

Negative control: Mutant c-Jun mRNA, which lacks the unique kink (the binding site).Negative control: Mutant c-Jun mRNA, which lacks the unique kink (the binding site).

Unrelated small molecule: c-Myc mRNA binder.Unrelated small molecule: c-Myc mRNA binder.

Demonstration of RNA-small molecule interactions by SPR:Demonstration of RNA-small molecule interactions by SPR:

In SPR assay, the small moleculeIn SPR assay, the small molecule c-Jun binder showed specificc-Jun binder showed specific binding towards WT form ofbinding towards WT form of c-Jun mRNA as compared to itsc-Jun mRNA as compared to its mutant form, such that uponmutant form, such that upon mutant subtraction, themutant subtraction, the sensorgram appear positive.sensorgram appear positive.

The unrelated small moleculeThe unrelated small molecule c-Myc mRNA binder did notc-Myc mRNA binder did not

Demonstration of target protein (BRD4) degradation by split Nanoluciferase assay:Demonstration of target protein (BRD4) degradation by split Nanoluciferase assay:

exhibit binding to the c-Junexhibit binding to the c-Jun mRNA, with the net effectmRNA, with the net effect

In HEK293 cells stably expressing LgBitIn HEK293 cells stably expressing LgBit nanoluciferase fragment, we knocked innanoluciferase fragment, we knocked inAssessing BRD4 degradation by HiBit-LgBit assayAssessing BRD4 degradation by HiBit-LgBit assay being marginally negativebeing marginally negative sensorgrams.sensorgrams.

the corresponding HiBit fragment at thethe corresponding HiBit fragment at the endogenous locus of BRD4.endogenous locus of BRD4.

The LgBit fragment has a high affinity for theThe LgBit fragment has a high affinity for the HiBit fragment, thereby reconstituting theHiBit fragment, thereby reconstituting the active NanoBiTactive NanoBiT(Nanoluciferase) enzyme.(Nanoluciferase) enzyme.

Demonstration of RNA-small molecule interactions by Fluorescent dye displacement assayDemonstration of RNA-small molecule interactions by Fluorescent dye displacement assay

Expression of BRD4 therefore,Expression of BRD4 therefore, creates an active nanoluciferase.creates an active nanoluciferase.

Degradation of BRD4 thus causes aDegradation of BRD4 thus causes a decrease in the Nanoluciferase signal.decrease in the Nanoluciferase signal.

Addition of small Addition of small molecule binder molecule binder

Demonstration of binary and ternary complex formation by SPR:Demonstration of binary and ternary complex formation by SPR:

Fluorescence readout showing displacement of the ToPro RNA binder by the c-Jun binder. As theFluorescence readout showing displacement of the ToPro RNA binder by the c-Jun binder. As the concentration of the c-Jun binder increases, fluorescence decreases. No displacement is observedconcentration of the c-Jun binder increases, fluorescence decreases. No displacement is observed with the mutant c-Jun mRNA.with the mutant c-Jun mRNA.

Next, we plan to demonstrate the ternary complex of RNA-RiboTAC-RNaseLNext, we plan to demonstrate the ternary complex of RNA-RiboTAC-RNaseL by SPR and evaluate the RiboTAC efficacy in cellular studies.by SPR and evaluate the RiboTAC efficacy in cellular studies.

Demonstration of target proteinDemonstration of target protein degradation by western blotting:degradation by western blotting:

HeLa cells transfected withHeLa cells transfected with the Nanoluc-BRD4(BD2)the Nanoluc-BRD4(BD2) plasmid and 24 hours laterplasmid and 24 hours later treated with indicatedtreated with indicated concentrations of MZ1 for 6concentrations of MZ1 for 6 hours. The cell lysates werehours. The cell lysates were analyzed by western blottinganalyzed by western blotting for the indicated proteins.for the indicated proteins.

• Future PlansFuture Plans
• DUBTACDUBTAC
• Autophagy-TArgetingAutophagy-TArgeting (Deubiquitinase-TArgeting(Deubiquitinase-TArgeting
• ChimeraChimera
• Chimera)Chimera)

DMPK

DMPK Capabilities o2h discovery operates a multi-modality integrated platform from Cambridge, UK, and Ahmedabad, India, with a focus on insight driven discovery.

1. Cell-permeability, CACO2-efflux, MDCK- MDR1, MDCK-MDR1-BCRP

2. PXR, CYP induction, HepRG, HepR

3. CYP enzyme, TDI, PgP, OATP1B1, BCRP

4. Blood plasma partitioning, plasma protein binding, hepatic uptake, OATP1B1 substrate

5. pKa, Solid, FaSSIF, Lung solubility

6. Hepatocyte, microsome clearances, met-id , CYP identification, Fuinc, chemical stability, chemical reactivity

• 7. UGT, SULT, other enzymes
• 8. Substrates
• 9. UGT identification, enzyme identification
• Wave 1
• Wave 2-3
• Wave 4

DMPK

Customised Assays

Tailored assays to meet niche research needs, including:

ChameLogK (Bio-availability of ‘beyond rule of 5’ molecules)

• Cathepsin Cleavage
• Soluble Epoxide Hydrolase (sEH) Stability
• Aldehyde Oxidase (AO) Phenotyping
• Photostability under Stress Conditions
• GST-mediated GSH Reactivity
• Instrumentation
• LC-MS/MS Platforms
• Multimode Plate Readers
• HPLCs & UPLC
• Liuid Handling Systems
• Cold Storage Š ‰eagent
• Management
• Why o2h discovery?

Our unique points-iased system provides an easy-to-use and cost-effective way to access feeiibe

ADME services: gp e tpepcw wmwpsewfescplpe&e tpefpewiwlw e woe ppederw two eplle tpeapaporwork

Experienced scientists with deep domain expertise

Customisable worfk氀ows for small molecules peptides and beyond

Agile team and rapid turnaround ideal for fast-moving biotechs

Clear reproducible and 氀exible reporting

Our

ADME services align with chemistry and biology to deliver cohesive insights

Contact us o2hdiscovery co o2h-discovery discovery o2h com o2h discovery o2hlife o2hgroup

Scan to visit website

DMPK

In-vivo Pharmacokinetics

We provide robust and reproducible in-vivo pharmacokinetics and pharmacology studies that drive discovery pipeline decisions

• PK Services
• Discrete and cassette studies
• Single-dose and repeat-dose
• Gender and food effect
• Dose proportionality
• Tissue distribution (e.g. brain uptake)
• Excretion studies
• Bio-avaibility
• Species/Animals Available
• Rat (Sprague Dawley, Wistar)
• Mice (Balb/C, Swiss Albino)
• Dogw (Begale)
• Rabbitw (New Zealand WãiteV
• Guinea Pig (Dunkin HartleyV
• Mini-pig
• Toxicology Services

General Acute tox, repeat-dose tox (í/êà/éç/æÜ days), Cãronic tox (êçÜ days)

Genetic Core Battery (AMES, Cãromosomal Aberration, MNT), Comet Assay

Developmental î Reproductive ÖECD àéê, àéé, Male fertility, ÖECD àêà, ÖECD àà 

• Disease-relevant Pharmacology Models (rodent-based)
• Oocology
• PC3
• (Prostate)
• SKOV3
• (O¯arian)
• Mia
• PaCa
• (Pancreatic)
• MOLT4
• (ALLf
• A549
• (Lung)
• HCT
• (Colon)
• MDA
• MB46q
• (Breast)
• A35
• (Melanoma)
• Metastasis model
• Iofm mtioo oodl
• Co llagen induced arthritis
• AdÚu¯ant induced arthritis
• DSS induced colitis
• TNBS induced colitis
• PMA induced psoriasis atopic dermatitis
• IMQ induced psoriasis atopic dermatitis
• Motor Skill
• Neurodegenerati¯e
• Disorder
• Y Ma4e test
• Neuromuscular diseases
• Four limù hanging tests
• CNS
• Neurotoximia
• LPS
• Induce
• Parkinson diseas
• ALZHEIMER
• S MÖDEL
• Metabolic Disorders model
• Osteoporosis
• TYPE
• Diaùetic oùes
• Aging study

Molecules to Medicines: Effective Pre-Formulation

Extensive characterization of drug substance, formulating the NCEs for pre-clinical studies

Formulation Expertise Driving the Transition from Discovery to Clinic

At o2h Discovery, we support biotech and life sciences innovators with comprehensive toxicology formulation services designed to accelerate preclinical development. Our expertise spans preformulation studies, preclinical formulations for PÈ evaluations, and the development of robust TO£ formulations prepared for dosing§

We also specialise in solubility and bioavailability enhancement strategies to ensure optimal drug performance. By integrating scientifc rigour with a collaborative approach, we help our partners streamline the transition from discovery to safe and effective clinical candidates.

• Comprehensive Pre-Formulation Solutions for Drug Discovery
• Discovery support
• Salt screening
• Drug solubilizer screening
• Determination of partition coeffcients
• Formulation stability
• Material characterization
• (solid-form)
• Polymorph and crystallinity studies
• Thermal characterization ~DSCw
• Solid-state NMƒs
• Particle size and size distribution
• Early pre-clinica formulation
• Self-emulsifying drug delivery systems ~SEDDSw
• Co-solvent techni que L ipid-based formulation
• Molecular dispersion
• Nanosuspension

Complexation

Our pre-formulation studies evaluate a broad spectrum of physical and chemical properties essential for designing the right formulation and delivery approach for your lead candidates. Backed by a team of expert scientists, we translate these insights into formulations that are effective, scalable, and compliant with regulatory standards.

Manage Your Integrated Drug Discovery Collaboration From Anywhere o2h.com/chemistry-in-the-cloud/

• New feature
• ELN features
• Project Management
• New Projects
• Communication & Data
• Starting Materials
• Performance, Admin & Tracking

ELN Step-by-Step

A structured, end-to-end experiment record – from brief to registered material

• Experiment Brief
• Reaction No. with hover-preview
• Reaction Scheme
• Standardised two-level classification
• Reaction Plan
• Scale, quantity, parallel type
• Supporting Literature
• Literature provenance tracking
• Chemical Calculations
• Inventory/Previous lots + deduction
• Risk Assessment
• ERA checklist – Low/Medium/High
• Experimental Text
• 4-section structured editor
• Multiple/Parallel Reactions
• Conditional – activated by Step 3
• Material Registration
• Closeout + three-tier hierarchy
• Quality Control
• Pre-lot QC with review workflow
• Operations
• Yield calculations & record closeout
• In Progress
• In Progress
• Live in Production
• Final Hardening in Progress

OBN Awards 2025 o2h Discovery won the “Best Industry Support Partner of the Year” Award at OBN Awards 2025.

Best Use of Technology Award

Chemistry in the Cloud has won the category

“Best Use of Technology Award” in the Pharma Industry Awards UK 2023.

Go Beyond Award (from I SL)

Nilesh Dagia, Chief Special Projects Officer at o2h discovery, won the 2019 I SL Go Beyond Award (Individual category) for leading

energy-efficient, eco-friendly lab design and execution.

OBN Awards 2023 o2h discovery won the “Most Impactful CRO of the Year” Award at the industry leading OBN Awards ceremony...

Models

Our campaign models are designed to give biotechs the head start they need to advance their drug discovery programs.

From Kickstarters to Biology Match Funding and the Peptide Guarantee, our initiatives open structured pathways that accelerate growth and move pioneering science toward its next milestone.

From idea to milestone, start generating data on the bench

Overview o2h discovery is serving up the o2h Biology Match Funding Award, an exclusive programme designed to give biotechs and big pharma an opportunity to smash through their discovery research projects!

With this award, we will match fund 50% of the FTE cost for projects up to $65K/£50K. It is designed to help you ace key milestones and rally your way to the next stage of funding or secure additional grants. It will also enable biotech research companies to tap into o2h’s vast expertise and resources, ensuring the delivery of impactful scientific results. With this initiative, we aim to foster a collaborative environment that drives scientific breakthroughs and promotes growth within the biotech ecosystem.

Programme highlights

Match Funding of up to 50% o2h will provide match funding for 50% of the FTE cost of biology research carried out with o2h discovery, for selected projects valued up to $65K/£50K.

Highly Experienced Biologists

Get access to work with our highly experienced team with a strong track record of >25 years delivering solid results to progress challenging biology projects.

Eligibility

This award is open to all sizes of biotech companies, big pharma, and academic institutions with novel drug discovery programs requiring biology research support. Early-stage startups must have secured initial funding or grants to qualify. T&C(1)

Evaluation

The applications will be evaluated by the match funding committee based on the programme's scientific potential, impact on human health, alignment with our in-house research capabilities, and (2)

other factors. This is a time-limited competition. T&C

Comprehensive Project Management

Expertise in executing and managing diverse biology projects, including target engagement, pharmacological profiling, target biochemistry, cell-based assays and more.

Access to Cutting-edge Equipment Suite o2h’s biology equipment capabilities include the Jess, Biacore T200 SPR, FLIPR Penta, CytoFlex, and more.

Terms & Conditions:

(1) The work package will be fully executed at o2h’s in-house research facilities and cannot be conducted in collaboration with any other CRO or organisation. Additionally, projects must fall within the scope of o2h’s biology research capabilities.

(2) Awardees will be announced within 3-4 weeks from the date of application.

[email protected] o2hdiscovery.co/biology-match-funding

A competitive award to turbocharge your biotech startup with a chemistry boost!

• Editions across the globe
• Awards provided so far
• $8.1M+
• Invested in resources

Give your startup a boost of chemistry...

Building on the success of our earlier Kickstarter competition, we have now launched the latest edition of o2h Kickstarter in “North America”, exclusively tailored for early-stage biotech companies that have secured initial funding, have exciting drug targets, and have the ability to scale, but need expert services to supercharge their chemistry efforts to meet the next scientific and funding milestones.

In essence, the award aims to support the next wave of biotechnology companies by providing a cost-effective team of six experienced o2h Discovery chemists, including two senior and four junior chemists. Despite o2h’s broader capabilities in Med Chem, ADME, and Biology Screening (in the UK and India), the goal is to keep the process straightforward and accessible.

Scan to find out more

Meet the Kickstarter Winners

Since its launch, the o2h Kickstarter Award has supported innovative biotech companies and academic spinouts from around the world, helping them generate critical scientific data and reach their next milestone.

Winning the o2h Kickstarter Award is a tremendous validation of our team's dedication to solving the MYC problem in cancer. The expertise and collaborative support provided by the o2h team are actively accelerating our hit-to-lead chemistry efforts. This partnership is instrumental in helping us rapidly advance our first-in-class MYC:TRRAP inhibitors from the laboratory toward the clinic, bringing us one step closer to addressing a critical unmet need in oncology.

Dr. Ed Feris CEO, cosMYC

We are deeply grateful to the o2h Kickstarter program for their invaluable support in advancing our small molecule discovery efforts. This partnership has enabled us to expand our compound portfolio and accelerate the lead optimization phase of our lead program. Support from initiatives like o2h Kickstarter plays a crucial role in helping early-stage biotech companies translate scientific innovation into tangible therapeutic opportunities

Ana Montalban CEO & Co-founder, Adularia

The Kickstarter has been pivotal for our development progress. Medchem can be expensive and challenging for early-stage biotechs, but we are now enjoying the momentum this high-quality chemistry programme brings to our lead optimisation. We had heard good things about the Kickstarter before we applied and I am happy to pass on that positivity from our own experience.

Rory Triniman CEO & Founder, Veirulence Ltd

• The o2h Kickstarter: Peptide
• The o2h Kickstarter: Peptide
• Exclusively oor Peptide-focused biotech startups
• Exclusively oor Peptide-focused biotech startups
• The o2h Kickstarter: Track Record
• The o2h Kickstarter: Track Record
• Editions across
• Editions across the globe the globe
• Awards provided
• Awards provided so far so far
• $7.2M+
• $8.1M
• Invested i
• Invested i resources resources
• About o2h Kickstarter: Peptide
• From Small Molecules to Peptides
• About o2h Kickstarter: Peptide

The o2h Kickstarter was originally launched to support

From Small Molecules to Peptides early-stage biotech companies in accelerating small-

The o2h Kickstarter was originally launched to support molecule drug discovery. Building on strong demand from early-stage biotech companies in accelerating smallthe biotech community, the programme now extends to molecule drug discovery. Building on strong demand from peptide therapeutics, with a dedicated edition designed for the biotech community, the programme now extends to startups working on peptide-based drug discovery.

peptide therapeutics, with a dedicated edition designed for startups working on peptide-based drug discovery.

This expansion re%ects the increasing role of peptides in modern drug discovery and o2hôs continued focus on This expansion reöects the increasing role of peptides in supporting innovation across modalities. The programme is modern drug discovery and o2h s continued focus on structured to enable progression from early hit supporting innovation across modalities. The programme is identifcation through to IID-enabling stages, with structured to enable progression from early hit integrated scientifc support to move programmes forward.

identifcation through to IID-enabling stages, with integrated scientifc support to move programmes forward.

• Programme
• Beneifts
• (What you get)
• Programme
• Beneifts
• (What you get)
• Peptide Synthesis
• Delivered with Precision

Peptide Synthesis

Delivered with High-purity linear and cyclic peptides, Precision including stapled and constrained formats, High-purity linear and cyclic peptides, enabling reliable library generation and including stapled and constrained formats, SAR exploration.

enabling reliable library generation and SAR exploration.

• End-to-End
• Chemistry
• Built for Execution
• End-to-end delivery for early-stage teams, End-to-End
• Chemistry

Built for Execution enabling rapid progression to proof-of-

End-to-end delivery for early-stage teams, concept without building in-house enabling rapid progression to proof-ofcapability.

• concept without building in-house capability.
• ADME
• Built Into the Programm e Includesp. 100
• complimentary
• ADME points
• ADME

Built Into the Programm e across both stages

• in Stagep. 1
• in Includesp. 100
• complimentary
• ADME points

Stage 2 to assess permeability, stability, across both stages and solubility early.

• in Stagep. 1

in Stage 2 to assess permeability, stability, and solubility early.

Biology Support on Demand

Extend your programme with expert

Biology Support on Demand biology support at 20 reduced cost, Extend your programme with expert covering target engagement, validation, biology support at 20% reduced cost, and assay development.

covering target engagement, validation, and assay development.

How it works?

The Keptide Kickstarter is structured in two stages, How it works?

giving startups both an initial discovery push and a The ;eptide Kickstarter is structured in two stages, clear pathway to continued support.

giving startups both an initial discovery push and a clear pathway to continued support.

Stage I - Discovery

A defned piece oo ork to Stage I - Discovery decision-relevant data enerate earlyy, A defned piece oo orr to enerate earlyy, decision-relevant data

In Stage I, Selected companies will receive:

100 peptides synthesis (linear & cyclic)

In Stage I, Selected companies will receive:

(at a fraction of the usual price)

• 100 peptides synthesis (linear & cyclic)p. 25

ADME data points a fraction of the usual price)

• 20 25 discount on Biology
• ADME data points
• F TEs
• End-to-end project managem entp. 20
• discount on Biology
• F TEs
• End-to-end project managem ent
• Stage II -
• Continued Developm ent

Dedicated support to advance your peptide pipeline

Stage II -

Continued Developm ent

Dedicated support to advance your peptide pipeline

Following a successful Stage I, participating companies can continue into Stage II and get:

Following a successful Stage I, participating

Dedicated

F TE engagem ent companies can continue into Stage II and get:

(at a fraction of the usual price for upto 6 months)

• Dedicated
• F TE engagem entp. 75
• (at additional

ADME data points a fraction of the usual price for upto 6 months)

• 20 75 discount on Biology
• F TEs additional
• ADME data points
• Focus on optimisation and further proiflingp. 20
• discount on Biology
• F TEs

Focus on optimisation and further proifling kickstarter o2h com o2hdiscovery co o2h-kickstarter-peptide

A new plug-and-play model for structuring a biotechA new plug-and-play model for structuring a biotech

OverviewOverview o2h Discovery has launched o2h Plug-in Biotech, a newo2h discovery has launched o2h Plug-in Biotech, a new dedicated service designed to help early-stage biotechdedicated service designed to help early-stage biotech companies establish and scale subsidiary-like operationscompanies establish and scale subsidiary-like operations in the UK and India.in the UK and India.

Changing the business model from Contract ResearchChanging the business model from Contract Research Organisation (CRO) to Contract Discovery OrganisationOrganisation (CRO) to Contract Discovery Organisation (CDO), the plug-in biotech is a plug-and-play operational(CDO), the plug-in biotech is a plug-and-play operational platform that will enable biotech founders and executivesplatform that will enable biotech founders and executives to retain strategic control while outsourcing executionto retain strategic control while outsourcing execution and administrative functions to o2h’s expertteams onand administrative functions to o2h’s expert teams on both sides of the world.both sides of the world.

Why choose us?Why choose us?

We have the core capabilities to help youWe have the core capabilities to help you set up your subsidiary-like biotech.set up your subsidiary-like biotech.

• ScalabilityScalability
• Skills & TalentSkills & Talent
• Speedy ExecutionSpeedy Execution

How do we help you?How do we help you?

We will provide all the required services to help youWe will provide all the required services to help you smoothly set up and run your biotech operationssmoothly set up and run your biotech operations [email protected]@o2h.com o2hdiscovery.co/plug-in-biotecho2hdiscovery.co/plug-in-biotech

An exclusive benefit that helps you deliver more value to your portfolio

About

Extending the o2h Kickstarter Award to More Biotech Innovators

Through the o2h Kickstarter Award, we've supported 45+ early-stage biotech companies across the UK, USA, Europe, Australia and Israel. Building on its success, we created the Platinum Partner Programme to help even more innovators access specialist drug discovery support during their earliest stages of growth.

The programme enables venture capital firms, venture builders, universities, incubators and technology transfer offices to extend the benefits of the o2h Kickstarter Award directly to eligible companies within their portfolio or ecosystem.

By combining investment and ecosystem support with o2h Discovery's integrated drug discovery expertise, Platinum Partners help founders generate critical scientific data, reduce development risk and accelerate progress towards key technical and fundraising milestones.

Benefits for Portfolio Companies

A dedicated team of six synthetic chemists for up to six months to accelerate small molecule discovery programmes

High-purity linear, cyclic and constrained peptide synthesis supports to rapidly expand peptide SAR programmes

100 complimentary ADME points and a 20% discount on biology services

Benefits for Platinum Partners

Integrated project management support delivered through o2h Discovery’s multi-disciplinary discovery teams

• Add Value Beyond Capital
• Strengthen Portfolio Success
• Differentiate Your Ecosystem
• A Trusted Discovery Partner
• Our Platinum Partners

A Match Funding Offer to Support CriticalA Match Funding Offer to Support Critical Proof-of-Concept StudiesProof-of-Concept Studies

Unlock high value ideas, assets and near misses... Unlock high value ideas, asset and near misses

We are in an era of exciting science. Pharma and biotech must make high-pressure decisions on deploying limited funds and resources to meet stakeholder expectations. The commercial biopharma model

Overviewdemands rapid progression of assets from preclinical to clinical stages to secure milestone payments and further funding. We are in an era of exciting new science. Pharma and biotech are often required to make extremely pressured decisions on the deployment of scarce funds and resources. The commercial biopharma o2h discovery Inflexion is a match funding offer of integrated biology, chemistry and analytical capabilities

Tx paradigm requires companies to quickly move promising assets from preclinical to clinical along a focused strategic journey to help access critical stakeholder support for milestone payments and further funding.for critical proof-of-concept studies. The risk is shared on a sweat equity, project share or milestones…

Tx mitigates against a delayed or missed opportunity by sharing some of the value in return for Inflexion mobilising these ideas with a structured program towards the next key go-no-go position. o2h discoveryWhere Inflexion can help?

Tx has evolved deep design experience for focused and efficiently structured POC studies leading to an early Inflexion supports opportunities where the science may still be experimental with few precedents, lacks

Tx signal that the science works. The expertise cuts across a range of modalities and integrates medicinal a dedicated champion, or has become stalled or parked. The model brings a fresh perspective to project chemistry, biological assay cascade design, DMPK and analysis. The match-funding offer is available in bundles of USD 100K, 250K, or 500K, allowing shared financial and scientific risk.rescue and turnaround, whether a clinical trial has failed, assets have fallen out of market favour, or they no longer fit within a therapeutic strategy, leaving other indications unexplored. Inflexion also backs

Tx contrarian opportunities that challenge prevailing industry trends.

Where it can help...

Through InflexionTx

, projects can regain focus and direction, unlocking value and advancing scientific

Inflexion can support...

opportunities where others may have seen only risk. It can provide critical support in scenarios such as:

New Modality Novel Hit Matter

Explore alternative Design assay cascade/modalities against an panel along with someexisting asset to explore early chemical matter.new IP space

Novel Hit Matter

Design assay cascade/ panel along with some

• Novel Contrarian early chemical matter
• Ideas
• Projects that go against
• Novel Contrarian prevailing industry trends.
• Ideas

Projects that go by hunch against prevailing industry trends

Novel Target Space

Using novel screening strategies, combining in silico approaches for target identification.

Novel Target Space Rescue After

Using novel screening strategies combiningSetback in-silico for targetStalled after pre-clinical identificationstudy data or clinical trial setback.

Rescue After Setback

Stalled after pre-clinical study data or clinical trial

Funding Gap setback Providing data to the program champion to unlock an asset.

Funding Gap

Providing data to the program champion to unlock an asset

Testing New Ideas

Explore alternative

Lead Optimisation modalities against an Advancing promisingexisting asset or target to leads into more potent,explore new IP space. development ready drug candidate molecules

Near Miss New Indications

An additional study Assets not aligned withboost may be required strategy but valuable into crack a scientific other indications.bottleneck

New Indicators

Assets not aligned with strategy but valuable in Creating Backup other indications

• Program
• Building up the pipeline
• Creating Backup behind the development candidate.
• Program

Building up the pipeline behind the development candidate

Near Miss

An additional study boost maybe required to crack a scientific bottleneck.

discovery models

models discovery

Over the years, we have become a trusted discovery partner to early-stage life science, biotech, and techbio companies, helping them translate innovative ideas into meaningful scientific progress and successful funding outcomes.

USA

Synprox

• UK & Europe
• Molecular Glue Labs
• Australia
• Israel

A passion for investing

We have a track record of nurturing and investing in emerging life science and tech companies.

Biotech is one of the leading sectors in the UK economy. The o2h Ventures team are leaders in the biotech community and have been actively involved as investors, holding various board/ industry positions as well as being engaged in grassroots scientific activity for over 20 years.

About us

Founded in 2018, o2h Ventures is a UK-based venture capital firm focused on investing in the next generation of biotech companies that are working to improve human health. Headquartered in Cambridge, o2h Ventures has invested over $10 million into more than 35 early-stage life science companies, with a particular focus on novel therapeutics and emerging technologies like AI and machine learning.

Many of the companies backed by o2h are tackling diseases with high unmet medical need—such as cancer, depression, infectious diseases, and age-related conditions—and several are university spinouts from institutions including Cambridge, Oxford, UCL, Dundee, and Nottingham.

o2h Ventures takes a hands-on approach, often leading investment rounds and supporting its portfolio companies through Board positions. The firm is authorised by the FCA and continues to invest from its tax-efficient funds into seed & pre-seed biotech companies that are now progressing toward commercial maturity and long-term impact.

• Biotech investments (~10M) over 6 years
• Clinical stage from Seed
• >$400M
• External finance leveraged

Seed to IPO 39x upon first listing TSX V:DMT

The UK is the biggest life science innovation hub in Europe o2h Ventures is headquartered in Cambridge, and we are housed in the Mill SciTech Park, which is wholly owned by the o2h Group. Our site is in close proximity to Cambridge University, The Wellcome Genome Campus, Babraham Institute, Astra Zeneca’s HQ, Moderna and one of the largest and best-known teaching hospitals in the UK: Addenbrookes Hospital.

The UK is a highly concentrated biotech cluster of which Cambridge UK is at the epicentre. Themes include AI-driven discovery platforms, next-gen small molecules, RNA Biology, psychedelics, Antibody Drug Conjugates, Immune Oncology, Lipid Nanoparticles, and Protein Degradation.

The Mansion House Compact, July 2023 a commitment by major UK pension funds to invest 5% of the $4.3 Trillion they hold into unlisted equities which could lead to significant further late-stage capital into Biotechnology companies.

The UK retained its position as Europe’s leading biotech hub, attracting 37% of total VC investment across the continent in 2024.

The UK recevies

41% of all Biotech fundind across Europe*

*Source: BIA Finance Report 2023

Developing IP for global markets with a lower people & infrastructure costs and lower valuations than the USA.

Cambridge

The UK’s Billion-Pound Biotech Engine

Cambridge has long been synonymous with academic brilliance, scientific discovery, and entrepreneurial spirit. Today, it has emerged as Europe’s leading hub for life sciences, anchored by world-class institutions such as the University of Cambridge and the Babraham Institute and in close proximity to major pharma and research centres.

Being embedded in Cambridge gives o2h Ventures unparalleled access to the most exciting spinouts and scientific founders. It also places us in the centre of a dense network of pharma, investors, and entrepreneurs—ensuring a constant flow of high-quality opportunities.

1 #2 Globally for innovation intensity in the UK

• Business and science parks
• Nobel laureates produced by Cambridge
• 162B

Enterprise value of Cambridge startups & scale-ups

Universities with global rankings (including Cambridge and Anglia Ruskin)

For investors, Cambridge represents a proven pipeline from discovery to scale-up, offering access to the next generation of biotech and technology leaders.

Being part of Cambridge’s biotech network gives us a unique window into tomorrow’s science. Unlike traditional funds that only see deals once they are in the market, we are embedded within the biotech ecosystem itself. Through o2h Ventures and o2h Discovery, we see science earlier, support founders at inception, and build trusted relationships long before others.

• d deals screened annually
• 250+ ventures
• Keystone Therapeutics
• 40+ o2h Ventureso2h Ventures PortfolioPortfolio

KickstarterKickstarter WinnersWinners o2h Discovery Kickstarter is a proprietary competition award that supports the most exciting early biotech ideas. Winners receive expert chemistry/ biology services, mentorship, and scientific support — giving us privileged visibility into innovation years ahead of the market. o2h Ventures builds on this by scouting opportunities across the UK and beyond, applying advanced scientific due diligence and backing the strongest ideas with capital, guidance, and access to the Cambridge ecosystem.

Access to early-stage innovation at good valuations

An integrated biotech engine

Co-investment opportunity rights

• Portfolio Evolution Across Key Milestones
• Therapeutics
• Discovery Preclinical Phase 1
• Phase 2
• Discovery
• Pre-clinical
• Phase I
• Phase II
• Phase III
• Discovery Preclinical Phase 1
• Phase 2

DiscoveryArea:PreclinicalCNS / NeurosciencePhase 1Focus:Phase 2Psychedelics Depression & Anxiety

• Discovery Preclinical Phase 1
• Phase 2
• Area: Ophthalmology
• Focus: Retinal - NPDR, DME
• Marketed
• Area: Inflammation / Dermatology
• Focus:Inflammatory Skin
• Area: CNS / Neuroscience
• Focus: Depression & Pain
• Discovery Preclinical Phase 1
• Phase 2
• Area: CNS / Neuroscience
• Focus: Psychiatric schizophrenia & depression
• CRO
• Area: Oncology
• Focus: ADCs - Leukaemia, Tumors
• Platform CRO
• Area: Otology
• PlatformCRO Platform
• Focus: Hearing Loss
• Platform

Platform Platform Area: Cardiovascular / Haematology CRO

• Focus: Clot Stabilisation
• Platform
• Platform Platform Platform Area: Oncology
• Focus: Solid Tumors
• Platform PlatformArea: PGene Editing / Multi-Therapeutics
• Focus: Programmable platform
• Discovery Preclinical Phase 1
• Phase 2
• Discovery Preclinical Phase 1
• Phase 2
• PlatformCRO Area: Anti-aging & Regenerative Medicine
• Focus: Ageing Pathways

Platform

Diverse biotech asset opportunities for future Diverse biotech asse opportunities for futurDiverse biotech asse opportunities for futur Diverse biotech ass opportunities for futu

• PlatformArea: Anti-Infectives
• Focus: Antibiotic Resistance
• Platform Area: Multi-Therapeutics Platform
• Focus: AI Drug Discovery
• Area: Oncology
• Focus: Targeting tumour biology
• Diverse biotech ass opportunities for futu
• Area: Oncology
• Focus: Targeted protein degradation
• Area: Oncology
• Focus: Antibody-based therapies
• Discovery Preclinical Phase 1
• Phase 2
• CRO CRO
• PlatformArea: Oncology Platform
• Focus: Virotherapy
• Platform Platform Area: Oncology
• Focus: Antibody-drug conjugates
• Platform Platform
• Platform
• Area: Respiratory / Multi-Therapeutics Platform
• Diverse biotech asse
• Diverse biotech ass

Focus: Idiopathic Pulmonary Fibrosis & beyond opportunities for futur opportunities for futu

Area: Metabolic disorders

Focus: Targeting obesity

• Platform Biotech
• Proof of concept
• Platform Validation
• Pipeline Expansion
• Strategic Partnership
• Clinical Advancement
• Commercial Readiness
• Market Leadership
• Area: Multi-Therapeutics
• Focus: Drug Delivery (Nanoparticles)
• Tech Bio
• Proof of concept
• Algorithm / Platform Validation
• Pipeline Expansion
• Strategic Partnership
• Clinical Advancement
• Commercial Readiness
• Market Leadership
• Area: Oncology Focus: AI Oncology Simulation
• Area: Multi-Therapeutics Focus: Quantum AI (Enzymes)
• Area: Cardiovascular
• Focus: AI Cardiovascular Discovery
• Area: Multi-Therapeutics
• Focus: AI Precision Dosing
• Area: Anti-Infectives
• Focus: AI Preclinical (Anti-Infectives)
• Medtech
• Pharma Enablers
• Concept & Prototype
• Preclinical / Bench Validation
• Clinical Validation
• Regulatory Approval
• Commercial Launch
• Market Expansion & Standard of Care
• Area: Cardiovascular
• Focus: Remote Heart Failure Monitoring
• Area: CNS / Neuroscience
• Focus: Portable Brain Injury Diagnostics
• Proof of concept
• Technology Validation
• Early
• Pharma Collaborations Partnerships
• Commercial Adoption
• Industry Standard
• Area: CNS / Multi-Therapeutics
• Focus: Ion Channel Discovery
• Area: Multi-Therapeutics
• Focus: Growth Factors (Stem & Regen)
• Area: Multi-Therapeutics
• Focus: Cell/Tissue Preservation
• Area: Multi-Therapeutics
• Focus: 3D Cell Culture & Testing

• Therapeutics
• Discovery
• Pre-clinical
• Phase I
• Phase II
• Phase III
• Marketed
• Area: Neurodegenerative
• Focus: Neurodegenerative protein degradation
• Area: CNS / Neuroscience
• Focus: OCD therapeutics
• Area: Neurodegenerative
• Focus: Alzheimer’s & Parkinson’s
• Area: Oncology
• Focus: ADCs
• Area: CNS / Neuroscience
• Focus: Psychedelics for CNS
• Area: Multi-Therapeutics
• Focus: Multi-therapeutic QTRT
• Area: Oncology
• Focus: Prostate Cancer
• Area: Multi-Therapeutics
• Focus: Anti-fibrotic therapies for Heart failure
• Area: TPD
• Focus: Protein degradation
• Area: CNS / Neuroscience
• Focus: PTSD & depression
• Area: Oncology
• Focus: AML, melanoma, CRC
• Area: Ageing & Regenerative Medicine
• Focus: Anti-aging molecules
• Area: Anti-Infectives
• Focus: Flagella inhibitors
• Area: Oncology
• Focus: Kinase inhibitors
• Area: Infectious Diseases/Autoimmune
• Focus: EBV & autoimmune inhibitors
• Area: Neurodegenerative
• Focus: Huntington’s TPD
• Area: Neurodegenerative
• Focus: Neurodegenerative & inflammatory
• Area: Oncology
• Focus: Cancer transcription inhibitors
• Area: Multi-Therapeutics
• Focus: Cancer, pain, dementia
• Area: Oncology
• Focus: Immunotherapy

• Discovery
• Pre-clinical
• Phase I
• Phase II
• Phase III
• Marketed
• Area: Oncology
• Focus: Prostate Cancer
• Area: Metabolic disorders
• Focus: Obesity
• Area: Multi-Therapeutics
• Focus: Oncology & Neurology
• Area: Oncology
• Focus: Precision oncology
• Area: Oncology
• Focus: Molecular glues (PPIs)
• Platform Biotech
• Keystone
• Synprox
• Proof of concept
• Platform Validation
• Pipeline Expansion
• Strategic Partnership
• Clinical Advancement
• Commercial Readiness
• Market Leadership
• Area: Targeted drug delivery
• Focus: Tissue-targeted drugs
• Area: Drug discovery
• Focus: Oncology drug discovery
• Tech Bio
• Proof of concept
• Algorithm / Platform Validation
• Pipeline Expansion
• Strategic Partnership
• Clinical Advancement
• Commercial Readiness
• Market Leadership

Area: Oncology & Immunology Focus: Protein-level disease mapping

• Pharma Enablers
• Proof of concept
• Technology Validation
• Early
• Pharma Collaborations Partnerships
• Commercial Adoption
• Industry Standard
• Area: Oncology
• Focus: Oncology drug discovery
• Area: Psychiatric & Neurological Disorders
• Focus: Cognitive Impairment, Schizophrenia

Area: Drug Discovery Focus: Neuroimmune drug discovery

The Integrated o2h Biotech Engine

From proprietary deal access to Big Pharma exit, o2h Ventures uniquely integrates discovery, incubation, community, and capital—de-risking early-stage science and creating outsized opportunities in biotech.

• Embedded in the biotech ecosystem
• Exclusive access to deal flow
• Biotech market insights
• Expert scientific due diligence
• Research & chemistry support
• Expert guidance, advisory network, pharma connections

Scout, invest in University Spinouts via our pre-seed SEIS Fund

• Close partnership
• Cambridge cluster ecosystem
• Active, hands-on mentoring and operational support
• Funding support via seed EIS Fund
• Collaboration opportunities across our portfolio

Access to labs and shared office spaces Networking, investor and pharma engagement events

Strategic mentoring, BD, and pharma intros

Raising larger rounds

Pathway to pharma licensing, partnerships, and exits

Next-gen biotech therapies on track to clinical & commercial milestones

Clear de-risked pathway designed to capture maximum value creation

Biotech Finance Across the Lifecycle o2h Ventures supports biotech companies through every stage, from inception to scale. Our SEIS fund provides early, tax-efficient capital to university spin-outs and founders, alongside mentorship and access to our Cambridge network. The Knowledge-Intensive EIS Fund offers follow-on capital to drive clinical and commercial growth. As our portfolio matures, the Seven Sisters Human Health Growth Fund backs de-risked, later-stage biotech companies ready to scale.

• Inflexion point
• Targetto-hit
• Hitto-lead
• Lead optimisation
• Pre clinical development
• Phase 1
• Phase 2
• Phase 3
• FDA submission
• Commercial

The o2h Seven Sisters Human Health Growth Fund

The UK consistently attracts over 40% of all biotech investment across Europe. Yet, despite world-class science, a persistent valuation gap with the US remains, driven not by weaker innovation, but by a shortage of growth capital at the crucial scaling stages.

A Seven later-stage human health companies from the o2h portfolio, with the clearest path to exit

A Clear 5–7 year exit horizon, mainly through trade sales

A Companies which have been significantly technically de-risked, with revenue or late-stage trials

A Access to UK biotech at attractive valuations

A Positioned for growth, scale, and meaningful exits

Our Seven Sisters Human Health Growth Fund will provide an opportunity to invest in some of the UK’s most exciting biotech companies at attractive entry points. Many of these businesses have already navigated significant technical risk, are either generating meaningful revenue or advancing towards late-stage clinical trials and, crucially, are at the stage where a single round of funding could accelerate them towards a clear exit pathway.

• Portfolio Overview - Clinical
• Company
• Therepeutic Area / Focus
• Description
• Modality
• Funds Raised
• Area: CNS /
• Developing psychedelic-based

Neuroscience therapeutics, including the deuterated psilocin analog CYB003, Focus:

to transform treatment for major

Psychedelics depressive disorder - Phase II (Depression, Preclinical Phase 1

• Phase 2
• Discovery Anxiety)Discovery Preclinical Phase 1
• Phase 2
• Area: Ophthalmology

Focus: Retinal (wAMD, DME)

University of Nottingham spinout developing small-molecule modulators of mRNA splicing to treat wet AMD and diabetic macular oedema, in collaboration with Janssen (J&J) - Phase II Inception

Small Molecule

Small Molecule

IPO - Exited to Cybin Inc. NYSE listed $425M

• Series A £9 28M
• Area:
• University of Dundee spinout

Inflammation / developing small-molecule

Dermatology therapeutics targeting stop codon mutations in cancer and Focus: Discovery Preclinical Phase 1genetic diseases through strategicPhase 2

• Inflammatory Discovery Preclinicalpartnerships -Phase 1
• Phase 2Phase II Inception
• Skin
• Area: CNS / CRO Neuroscience

Focus:Platform CRO

Depression & PainPlatform Platform Platform Area: CNS / Platform Neuroscience Platform Focus:Platform PsychiatricCRO (Schizophrenia, PlatformPlatform Depression)

• Platform
• CRO
• Platform
• Platform
• Platform
• Platform
• Platform

Platform

Developing oral, abuse-deterrent ketamine formulations (Keticap) for treating depression, bipolar disorder, and other mood-related conditions - Phase II Inception

Advancing precision psychiatry and neurology through digital biomarkers and novel CNS compounds to deliver targeted treatments for defined patient subtypes - Phase I

• Small Molecule
• Seed £3 35M
• Small Molecule
• Series A £8 39M
• Small Molecule
• Series A Divers
• £6 87M opportu D opp
• Diverse biotech asset opportunities for future
• Diverse biot opportunities

• Portfolio Overview - Pre-Clinical
• Company
• Therepeutic Area / Focus
• Area: Oncology
• Focus: ADCs (Leukaemia, Tumors)
• Area: Otology
• Focus: Hearing Loss
• Area: Cardiovascular / Haematology
• Focus: Clot Stabilisation
• Area: Oncology
• Focus: Solid Tumors
• Area: Gene Editing / Multi- Therapeutics
• Focus: Programmable Gene Editing Platform
• Area: Ageing & Regenerative Medicine
• Focus: Ageing Pathways
• Area: Anti- Infectives
• Focus: Antibiotic Resistance
• Description

Modality

Developing highly selective cancer therapies using proprietary “twin antigen fingerprint” technology to enable precise Bi-Cygni treatments that target the cancer, not the patient.

Developing lipid nanoparticle-based mRNA therapies to regenerate inner ear cells and transform the treatment of hearing loss.

University of Leeds spinout developing a next-generation small molecule to outperform tranexamic acid and transform bleeding management across clinical settings.

Developing the CASPAROV platform to uncover novel drug targets and biomarkers by analysing tumour diversity driven by chromosomal instability in complex cancers.

Developing a novel gene modulation technology with broad applications, offering new therapeutic possibilities for patients with rare diseases.

• Small Molecule
• Small Molecule
• Biological
• Small Molecule
• Small Molecule

Biological & Cell

Developing small-molecule therapeutics targeting novel mechanisms to prevent or delay age-related diseases and promote healthy longevity.

University of Oxford spinout leveraging AI-driven drug discovery to develop novel therapeutics for oncology and high-threat pathogens, supported by validated in vivo data.

• Small Molecule
• Digital & Small Molecule
• Funds Raised
• Series A £2 91M
• Seed £2 45M
• Seed £845K
• Series A £1 70M
• Series A £7 25M
• Seed £870K
• Series A £13 97M

• Company
• Portfolio Overview - Pre-Clinical
• CRO
• Therepeutic Area / FocusPlatform
• Description
• Modality
• Funds Raised

6 1 x 1 x 2 x

• Platform
• Area: Multi-
• Cambridge University spinout using
• Digital

Pre-series A Platform its AI-enabled chemSEEK platform Diverse biotech assets and d& Small

• Therapeutics
• £9 66M
• Platform to discover novel small molecules
• Molecule opportunities for future invest
• Focus: AI DrugPreclinical Phase 1
• Phase 2
• Discovery with antibody-like specificity against
• Discovery challenging targets.
• Area: Oncology

University of Bath spinout

Focus: Tumor Targeting developing constrained peptide drugs to target “undruggable” transcription factors, with an initial focus on cancer targets like Discovery Preclinicalpaediatric high-grade gliomas.Phase 1

• Phase 2
• Small Molecule
• Seed £431K
• *Small Ph
• Area: Oncology
• Focus: Targeted Protein Degradation
• CRO

Using its proprietary SITESEEKER phenotypic screening platform to identify previously “undruggable” targets and develop novel therapies across multiple diseases.

• Small Molecule
• Series B Extension £61 75M
• Area:PlatformOncology
• Focus:
• Platform
• Antibody Tx
• Platform

Platform

University of Sussex spinout developing small-molecule cancer therapies targeting the LMTK3 kinase pathway, with an initial focus on breast cancer.

• Area: Oncology
• Creating IV-deliverable viral immunotherapies to reprogram
• Focus:
• the immune system against solid
• CRO
• Virotherapy tumors and metastases.
• Discovery Preclinical Phase 1
• Phase 2
• Platform
• Small Molecule
• Seed £609K
• Diverse biote opportunities fo
• Biological
• Seed
• & Cell
• £796K
• Area:PlatformOncology
• Focus: ADCs
• Platform

Platform

Cambridge University spinout developing next-generation ADCs using its multivalent ELIVATE technology to unlock new payloads and enhance cancer treatment.

• Small Molecule
• Pre-series A £3 54M
• Diverse bio opportunitie
• Area: Respiratory / Multi- Therapeutics

Focus: Idiopathic Pulmonary Fibrosis (IPF) and beyond

University of Nottingham spinout developing small-molecule RGD integrin inhibitors for IPF, liver and kidney diseases, and cancer.

Small Molecule

Seed £1M

• Portfolio Overview - Pre-Clinical
• Company
• Therepeutic Area / Focus
• Area: Multi- Therapeutics
• Focus: Drug Delivery (Nanoparticles)
• Area: Oncology
• Focus: AI Oncology Simulation
• Area: Multi- Therapeutics
• Focus: Quantum AI (Enzymes)
• Area: Cardiovascular
• Focus: AI Cardiovascular Discovery
• Area: Multi- Therapeutics
• Focus: AI Precision Dosing
• Area: Anti- Infectives
• Focus: AI Preclinical (Anti-Infectives)
• Description

Modality

UCL spinout pioneering nanomedicine with its polyNaut platform to deliver genetic therapies to hard-to-reach sites such as the brain, CNS, and lungs.

Platform Tech

Using AI to create predictive “Simulated Cell” models that accelerate and optimise drug discovery, with a focus on cancer treatment.

Using AI and quantum-driven screening to discover potent transition state protein inhibitors across multiple therapeutic areas.

Digital Health

Digital Health

Cambridge University spinout using computational and omicsdriven approaches to decode cardiovascular disease biology and discover novel therapeutics.

Digital Health

Developing software-driven precision dosing technology that integrates drug monitoring and pharmacology to optimise treatment across cancer and infectious diseases.

Using AI and multi-omics data to build “OrganoMaps” that reveal disease mechanisms and accelerate drug discovery across therapeutic areas.

• Digital Health
• Digital Health
• Funds Raised
• Series A £22 90M
• Series A £7 73M
• Seed £4 98M
• Seed £6 82M
• Seed £1 79M
• Seed £505K

• Portfolio Overview - Tech Bio
• Company
• Therepeutic Area / Focus
• Description
• Modality
• Area: Digital Health / Multi- Therapeutics

Focus: Oncology Support (Pediatrics)

Digital health platform using AR and interactive games to help children understand medical procedures, reducing anxiety through engaging, avatar-led experiences.

• Digital Health
• Area: Cardiovascular
• Focus: Remote Heart Failure Monitoring
• Area: CNS / Neuroscience
• Focus: Portable Brain Injury Diagnostics
• Area: CNS / Multi- Therapeutics
• Focus: Ion Channel Discovery
• Area: Multi- Therapeutics

Focus: Growth Factors (Stem & Regen)

Developing AI-powered, contactless monitoring technology that tracks foot volume changes to detect heart failure early and reduce hospital readmissions.

Digital / Medical Device

Developing portable, wearable brain imaging devices using functional Near-Infrared Spectroscopy (fNIRS) for rapid, point-of-care diagnosis and monitoring of traumatic brain injuries.

Digital / Medical Device

Preclinical CRO specialising in ion channel screening, cardiac safety, and neuroscience assays to support pharma and biotech research.

Small Molecule

Cambridge University spinout producing premium, functionally pure recombinant proteins using proprietary E. coli purification technology to improve research reproducibility.

• Biological & Cell
• Funds Raised
• Seed £425K
• Series A £4 93M
• Seed £3 60M
• Series B £8 30M
• Series A £9 21M
• Area: Multi- Therapeutics

Focus: Cell/ Tissue Preservation

Using alginate hydrogel technology to extend biological sample shelf life, backed by strong IP and leadership.

Area: Multi- Therapeutics

Focus: 3D Cell Culture & Testing

Developing in vitro cell-based assays to replace animal testing in the production of clostridial neurotoxinbased therapeutics.

• Biological & Cell
• Seed £4 13M
• In vitro / Cell-based Assay Technology
• Pre-seed $300K

The o2h chaitime portfolio pitch day introduces a new format to our chaitime series, transitioning to an in-person event with a simultaneous webinar. It is designed to foster collaboration, create investment opportunities, and facilitate the exchange of innovative healthcare ideas within a global investor network.

This event serves a dual purpose: Connecting o2h Ventures’ portfolio companies with biotech investors worldwide and providing a platform for these portfolio companies to showcase their potential, interact with experienced investors, and build a potential pipeline for their funding round.

• Editions
• Portfolio Company Pitches
• 1M in Investments Confirmed till Date
• In-Person Investors Engaged
• Global Participants via Zoom

We partner with accelerators, incubators and seed stage companies to support their digital transformation journey through all phases of software development services including planning, design, development and implementation life science

The o2h team are leaders in the biotech community and have been actively involved as investors, service providers, and holding various board positions. We have been engaged in grassroots scientific activity for over 20 years.

technology

We have the capabilities to build customised product and special project builds covering all stages of the product development lifecycle covering design, development and adoption.

We are co-located with a community of innovators and seed stage companies in o2h incubator at Hauxton House, Cambridge, UK.

Our Services

We have developed and launched 50+ projects across web and mobile applications

Product Development

We consult, support and implement the entire product life cycle, from the initial launch of an MVP to ongoing support of the live product. Our expertise lies in product development within the life sciences, technology, and green innovation sectors.

Gen AI

We design and implement cutting-edge generative AI solutions tailored to your business needs, from custom model creation to seamless integration. Our expertise spans text, image, and audio generation, unlocking innovation and efficiency.

Cloud Technologies

By utilising cloud-based applications, organisations can eliminate the complexities of building and maintaining application architectures. We specialise in AWS, Google Cloud, and Azure.

QA Automation

Modern digital applications need to scale rapidly and efficiently. Our team of experienced QA engineers excels at designing highly effective automated tests, including functional, regression, performance, and load testing, to ensure optimal performance and scalability.

Mobile Application

Mobile can serve as a standalone entry point or complement a web application. We ensure your app is elegantly designed across your chosen platform(s). Our expertise spans iOS, Android, Hybrid, Flutter, and React Native technologies.

Website Development

In today’s fast-paced world, we deliver best-in-class, scalable web applications. Leveraging the latest web technologies such as WordPress, HTML5, CSS3, JavaScript, and TypeScript, we tailor solutions to perfectly align with your needs.

AR & VR Development

We help businesses craft immersive experiences for their customers through comprehensive AR/VR development services. Our offerings include ideation, design, development, testing, deployment, and ongoing maintenance and support.

Blockchain Development

We help businesses leverage the power of decentralised technology. Our team of experts specialise in creating custom blockchain solutions tailored to business needs, including smart contracts, decentralised applications (dApps), and more.

Cyber Security

We offer a range of cyber security services that are designed to help you safeguard your data and IT infrastructure from a wide array of risks, including malware, hacking, phishing, and more.

Tech Kickstarter Competition

Give your startup a tech boost…

We have launched the o2h tech kickstarter competition to provide a boost of tech software/web development to seed stage companies who have secured some initial funding and are looking forward to build MVPs, Web or Mobile apps to kickstart their digital journeys or supercharge their existing MVPs by expanding their functionality with additional resources.

At o2h technology, we love working with innovative early stage companies and help them build tech products that have an impact on human and planet health. We enable our clients’ digital transformation journeys through all phases of software development services, including design, development, and implementation.

Scan to find out more

Identifying and Executing Quick-Win Generative & Agentic AI Use Cases in Life Sciences

About Polaris o2h has been working at the intersection of technology and life sciences for over two decades, supporting both large pharmaceutical companies and emerging biotechs across discovery, technology, and AI/digital transformation projects.

AI is driving signifcant change across the life sciences sector. The pace of change is quicker and the gap between what

AI is capable of and what organisations are actually implementing needs constant attention.

At o2h Technology, we have launched Polaris, a new AI implementation offering designed specifcally to help life sciences organisations move quickly into practical execution.

Polaris is focused on helping organisations identify and execute early quick-win AI use cases using the latest generative and agentic tools. The focus will be improve workfow effciency, unlock new opportunities, and help teams build direct hands-on experience with AI tools, data, processes, and applications. The early wins would then provide a beachhead for deeper and more wide ranging projects during a second phase of work.

• Two Easy-to-Access Starter Packages
• Limited time offer ending July 31st
• Ignite

6 Weeks Engagement

A practical starter package for identifying opportunities or pain points for a modest exploration of 1-2 use cases.

Accelerate

16 Weeks Engagement

An extended engagement focused on implementation, orchestration, and building early

GenAI and/or

Agentic AI workfows with 2-3 use cases with a modest scope or 1-2 use cases at a deeper level.

• Scale
• Transform
• Custom
• Customised

Engagement

Designed for organisations looking to scale AI capabilities, operational integration, orchestration, and longterm transformation initiatives.

Through

Polaris we will work with you to help build

• The orchestration layer
• The data layer for AI enablement
• Early
• GenAI and Agentic AI use cases

Practical AI workfows designed to improve operational effciency and unlock measurable value

Direct organisational experience with AI tools, data, processes and applications

• We can also explore
• Agentic AI use cases
• AI-enabled digital workforces

Practical AI applications within regulated life sciences environments

Polaris is designed to help organisations identify opportunity or performance gaps, and engage in AI experimentations during a phase one, and step towards a structured, scalable, and more measurable implementation in a second phase.

*Additional terms, conditions, timelines, deliverables, and commercial considerations may apply depending on organisational requirements, technical complexity, and programme scope.

techn [email protected] o2h-tech o2htechn ology o2htechn ology o2htech

Revolutionising Genetic Engineering with Version Control Solutions

• Industry: Biotechnology
• Location: United Kingdom
• Project Timeline: 2024 to Present
• Collaboration Model: Fixed Price

Services: Business Analysis, Design, Development, Quality Assurance, DevOps, Senior Technical Consultation

Project Description

CellRepo is an innovative platform tailored for genetic engineering, providing a centralised structure for version control for the experiments.

By introducing concepts from software development into bioengineering, CellRepo enables researchers to log, track, and collaborate on genetic modifications with precision, security, and ease.

Problem Statement

Traditional processes for tracking genetic modifications are manual, fragmented, and prone to errors, lacking a unified system that ensures consistency and collaboration.

CellRepo aims to bridge this gap by digitising and simplifying data management in genetic engineering, ensuring precision, security, and compliance with regulations.

• Key Challenges
• Version Control for Genetic Engineering
• Collaborative Workflow
• Data Integrity & Security
• Git-Like Project Structure
• Proposed Solution

1. Centralised Data: Unified platform with advanced search and categorisation.

2. Genostamp™: Tracks all genetic strain changes for accuracy.

3. Secure Setup: Heroku hosting with encrypted AWS S3 storage.

• Insights
• Increased collaboration & research efficiency
• Decreased administrative overhead
• Improved regulatory compliance

• Transforming Museum Experiences with AI
• Industry: Arts, Culture (EdTech)
• Location: United Kingdom
• Project Timeline: 2024 to Present
• Collaboration Model: Fixed Price

Services: Business Analysis, Design, Development (Web, Mobile, Gen AI), QA, DevOps, Sr. Tech Consultation

Project Description

SimplyArt AI is a mobile and web platform that transforms museum engagement by enabling digital exhibits and immersive onsite or virtual exploration. With AI-powered Q&A, natural voice narration, and adaptive tours tailored to visitors, it makes cultural content more interactive, inclusive, and accessible, earning recognition as our 3rd Kickstarter winner.

Problem Statement

Younger, digital-first audiences quickly disengage from traditional museum tools like plaques and static guides, making museums risk losing relevance. Accessibility challenges further limit engagement for visitors with learning differences. SimplyArt AI was created to solve these gaps with more interactive and inclusive experiences.

• Key Challenges
• Accurate and Context- Aware AI Responses
• Embedding Accessibility Seamlessly
• Harmonising Innovation with User-Centred Design
• Proposed Solution

1. AI-Driven Personalisation: Interactive Q&A, AI narration, and adaptive tours tailored to each visitor.

2. Accessibility-First & Scalable: Built-in inclusive features with seamless, multi-museum content management.

• Insights
• Boosting Visitor Engagement with AI
• Embedding Accessibility by Design
• Future-Ready Museum Operations

Extensive Track Record of Collaborations in Tech

Over the years we have provided tech expertise to many companies in life science, AI/tech and green innovation.

• Tech
• Life Science
• Green Innovation
• Health Tech
• HR Tech
• Bio Tech
• WARUKSHA

LABORATORIES PVT. LTD. One Goal, One Passion - Innovation

• Manufacturing
• Market Place
• E-commerce

collaborators technology

Shaping one of the region’s most exciting community of entrepreneurs in life science, and technology

incubator i n c u b a t o r the mill scitech park o2h incubator operates the mill scitech park in Hauxton, Cambridge, a place for entrepreneurs, scientists, techies & dreamers. Supported by high specification labs to create a genuinely unique environment for creativity and innovation to thrive.

We are quite obsessive about playing our part in the creation of a global collaborative community around innovation because we believe it’s the cross fertilisation of ideas across boundaries that spurs exciting new ideas, and well, we just can’t help doing what we love.

2.762.76 acres of stunningacres of stunning English countrysideEnglish countryside

buildings blendedbuildings blended from different erasfrom different eras

2,3982,398 sq.m of boutiquesq.m of boutique office and lab spaceoffice and lab space

Hauxton House a studio style workspace for life scientists & techies

An incubation model like no other

We have a passion for collaboration and look forward to shaping a closely integrated community of founders, students, academics, experienced entrepreneurs, senior managers, mentors, angels and VCs.

The vision of o2h group is to seed new ideas in life science, technology and green innovation by co-investing, co-creating and co-executing across boundaries.

The experience sharing from your peers (we prefer not to call it mentoring) will just flow, it’s in our DNA. You can also expect a constant stream of interesting people to come through our doors, it’s quite an intimate setting, so we will make an intro, make you both a coffee and you can do the rest...

Hauxton House incubator

Hauxton House

Hauxton House incubator

Building a Community o2h is a community-aware company working with organisations on a wide range of programs. We connect scientists, entrepreneurs, and society through initiatives from planting 100,000 trees to hosting Women’s Open Day, Influencer Bootcamps, Biotech Bikers and Cambridge Wide Open Week.

By opening our doors to investors, innovators, students, and residents, we help shape the future of science with the community.

The Cambridge TechBio Caucus

An experimental caucus to learn how we can nurture the world leading techbio space in Cambridge...

We were delighted to launch the first inaugural interactive conversation of the Cambridge TechBio Caucus (CTBC) with some of its leading players in the space. The Cambridge ecosystem is a leader in tech and life sciences and is home to some of the most exciting TechBio companies in the world.

The participants share their views on a broad range of topics including but not limited to the recent market volatility, the need to communicate how the biology works and detailing various viable business models that investors from both the tech and life science community can buy into. If you would like to join our Cambridge TechBio Caucus micro community which we organise in conjunction with Bits in Bio please do get in touch.

Hauxton House, Mill Scitech Park, Cambridge o2h incubator organises two influencer bootcamps events per year, one covering life sciences and one covering tech. Looking far beyond the ‘start-up’ skills the idea is to bring together a group of people who we call the ‘Dirty Dozen’, who are proven in getting their hands dirty helping the British tech economy flourish. We try to nurture a vibe that is an intimate space for exchange of thoughts and not a typically rigid classroom/panel/ conference format where you are only expected to only listen. We hope that the dirty dozen tackle subjects in depth, disagree and stir up a little controversy!

We cover a range of subjects from economic landscape, strategy, creativity, technology trends, customers/ investors, deals/exits, the role of Cambridge but more importantly we allow for personal stories, workshops, debate and masterclasses. The invites include influencers covering from the quintet of (1) Small co technical experts and CXOs, (2) Big co’ Managers/Executives, (3) Academia/ Profs, (4) Policy Makers and (5) Incubators & Seed/VCs.

A drop-in open conversation with Coffee, Masala Chai & Sandwiches

The AIM (Accelerator, Incubator, Mentoring) squad is a no agenda highly casual meeting held every quarter at the o2h incubator on subjects we care to talk about over masala chai, sandwiches and coffee. This is not an event where the invite is based on seniority, neither is it invite only, so we share with any colleagues who we think are like minded even if they are new to our line of work, we want to be inclusive and open to all experience levels.

The overall objective is over time to develop a more co-ordinated punch for what we do. The vibe is that our small intimate group of attendees sit around our farmhouse style table indoors or in the garden overlooking the meadows/brook and just let it flow…

Cambridgesquared

Building a global community of medicinal chemists and biologists o2h group believes in collaboration in drug discovery

The o2h group has been building a global community of medicinal chemists and biologists between Cambridge, UK and Cambridge, Boston, Massachusetts. The o2h group has organised well attended bar nights to date and plan to supplement this with a technology platform to encourage collaboration, representation, sharing of career opportunities, and importantly provide a first port of call or a safe space to discuss any future entrepreneurial ventures they or others are considering. We are planning to extend Cambridgesquared to other hubs such as San-Francisco, San-Diego, Singapore, Bangalore, etc.

community

Accessing Public Market Liquidity Inside High-Density Ecosystems

The Cambridge Stock Exchange Project is creating a platform for private companies who are scaling up to access liquidity from the market inside in the UK.

The Opportunity

The UK produces world-class science and technology companies — but often loses them before they reach their full potential. Breaks in the funding continuum, limited liquidity options, and short funding cycles leave companies vulnerable to premature acquisition or relocation to the USA, disconnecting them from their home ecosystems and creating significant lost economic opportunity for the UK.

The Cambridge Stock Exchange Project (CSEP) brings capital market liquidity into high-density innovation-led ecosystems.

CSEP bridges the gap between local private funding ecosystems and capital markets by providing liquidity pathways for UK science and technology ventures that are not yet ready for a full market listing or would benefit from remaining independent.

Through its strategic partnership with JP Jenkins, CSEP helps growth-stage companies access an FCA-regulated venue offering secondary market liquidity.

Who is it for?

Growth Stage Companies High-potential UK science and technology companies seeking access to regulated market liquidity, strategic resources, and investor networks while preserving innovation, leadership, and economic contribution within the UK.

Investors JP Jenkins provides a transparent, regulated mechanism for investors and shareholders to buy and sell shares through a network of 50+ UK-regulated brokers.

The CSEP Funding Continuum

The CSEP Funding Continuum is a long-term roadmap connecting UK science and technology companies with capital providers, exchanges, and institutional partners — from grant funding through to public markets.

CSEP is beginning where the gap is greatest: connecting growthstage UK companies with regulated market liquidity through its strategic partnership with JP Jenkins.

• Stages: Grant Providers
• Pre-Seed
• Seed
• Series A Global Exchanges
• Managed Funds & ETFs
• Series B
• Series C
• CSEP
• For more information please visit cambridgestockexchangeproject.com

Cambridge Stock Exchange Project Limited is not authorised or regulated by the Financial Conduct Authority and does not provide investment advice, arrange deals in investments, or solicit investors. Secondary market liquidity and primary capital raising services are provided exclusively by JP Jenkins Limited, authorised and regulated by the Financial Conduct Authority (FRN 1037394). The information provided is for informational purposes only and does not constitute a financial promotion or offer to buy or sell securities. Investments can go down as well as up. Cambridge Stock Exchange Project Limited is incorporated in England & Wales (No. 15764768).

Contact us at [email protected]

A WEEK OF LIFE SCIENCES @ THE HOME OF LIFE SCIENCES

SUPPORTING INCLUSIVE COLLABORATION

In March 2023, the government published its new strategy to make the UK a science and technology superpower by 2030. The plan draws on industry, finance, academia and civil society to realise its ambition. Cambridge has long championed collaboration, establishing itself as one of the leading science and technology clusters in the world. A reputation built on world-leading innovation, fast-growing science and tech companies, academia, and innovation centres - underpinned by investment, people and skills. To support and further progress this world-leading position requires inclusive collaboration across the Cambridge community.

Designed to provide the whole community with a chance to visit and experience the cluster first-hand, the o2h group first launched Cambridge Wide Open Day. Following its remarkable reception, the event evolved into a full-week celebration: Cambridge Wide Open Week.

INSPIRING OUR COMMUNITY

Cambridge is alive with ideas, funding, IP, exciting companies, and new facilities. Cambridge Wide Open Day encourages inclusive collaboration, vital for the region’s continued growth. You can engage with the broader community, facilitating introductions to investors, finding bigger premises, or inspiring the next generation workforce. The event opens doors for local residents, as well as visitors from across the UK and the world, to see what happens behind the closed doors of pioneering life sciences, technology, and green innovation companies.

ABOUT CAMBRIDGE WIDE OPEN WEEK (AKA Combined Ways of Working)

2025 marked the successful debut of Cambridge Wide Open Week (CWOW), a week-long festival of innovation, science, and collaboration held from 9th–13th June. The event showcased Cambridge’s pioneering companies, research labs, and innovation spaces, providing investors, founders, students, policymakers, and the wider community with a unique behind-the-scenes experience of one of the world’s most dynamic life sciences ecosystems.

CWOW 2025 featured the flagship Cambridge Wide Open Day on 11th June, the two-day Ventures Tour highlighting emerging biotech and techbio companies, Biotech Bikers rides, networking receptions, and a variety of conferences, talks, masterclasses, and workshops.

Building on this success, Cambridge Wide Open Week 2026 returns from 11th–19th June 2026, with fresh ideas, larger stages, and new opportunities for you to connect, collaborate, and celebrate Cambridge’s world-leading life sciences ecosystem.

• CWOW 2026 SCHEDULE - WHAT'S ON!
• THURSDAY 11TH JUNE
• VENTURES TOUR - OXFORD
• 9:00 AM - 10:15 AM
• OXFORD LAUNCH

BREAKFAST (INVITE ONLY) Welcome speech, registration and breakfast

Oxford Science Enterprises, 46 Woodstock Road, Oxford OX2

• 10:15 AM - 11:15 AM
• PITCH 1: OXFORD SCIENCE ENTERPRISES
• Investor showcase + networking

Oxford Science Enterprises, 46 Woodstock Road, Oxford OX2 6HT

11:35 AM-12:40 PM PITCH 2: OXFORD VENTURE ANGELS + LONGWALL VENTURES Investor showcase networking

Saïd Business School, Park End Street, Oxford OX1 1HP

Ⓒ 1:00 PM - 2:15 PM

LUNCH & NETWORKING Inventa, Botley Road, Oxford OX2 OHA

2:15 PM - 3:05 PM PITCH 3: OXFORD UNIVERSITY INNOVATION Investor showcase networking

• Inventa, Botley Road, Oxford OX2 OHA
• 3:05 PM - 4:25 PM
• PITCH 4: OXFORD
• TECHNOLOGY MANAGEMENT
• Investor showcase + networking
• Inventa, Botley Road, Oxford OX2 OHA
• COMMUNITY

5:30 PM - 8:00 PM DRINKS RECEPTION HOSTED BY BIOUK

(INVITE ONLY)

Drinks and networking reception

Grassroots, 46 Woodstock Road, Oxford OX2 6HT

FRIDAY 12TH JUNE

VENTURES TOUR -

LONDON

9:00 AM - 10:00 AM LONDON LAUNCH BREAKFAST (INVITE ONLY) Welcome speech, registration and breakfast

The Francis Crick Institute, 1 Midland Road, London NW1 1AT

10:00 AM - 11:15 AM

PITCH 1: KQ LABS Investor showcase networking

The Francis Crick Institute, 1 Midland Road, London NW1 1AT

11:40 AM - 12:45 PM PITCH 2: MERCIA VENTURES Investor showcase + networking London Stock Exchange, 10 Paternoster Square, EC4M 7LS

12:45 PM 1:45 PM

LUNCH & NETWORKING London Stock Exchange, 10 Paternoster Square, EC4M 7LS

1:45 PM - 2:25 PM

PITCH 3: FORESIGHT GROUP Investor showcase networking London Stock Exchange, 10 Paternoster Square, EC4M 7LS

2:50 PM - 4:00 PM PITCH 4: LIFEARC VENTURES Investor showcase networking

Victoria House, Bloomsbury Square, London WC1B 4DA

4:05 PM - 5:00 PM PITCH 5: PIONEER GROUP Investor showcase + networking Victoria House, Bloomsbury Square, London WC1B 4DA

COMMUNITY

5:00 PM - 7:00 PM DRINKS RECEPTION HOSTED BY PIONEER GROUP (INVITE ONLY) Drinks and networking reception

Victoria House, Bloomsbury Square, London WC1B 4DA

MONDAY 15TH JUNE

VENTURES TOUR - CAMBRIDGE (DAY 1)

8:45 AM - 9:45 AM CAMBRIDGE LAUNCH BREAKFAST (INVITE ONLY) Welcome speech, registration and breakfast

The Glasshouse, Innovate Cambridge, Botanic House, 100 Hills Road, Cambridge CB2 1PH

9:45 AM 10:50 AM

PITCH 1: AMADEUS CAPITAL PARTNERS Investor showcase + networking The Glasshouse, Innovate Cambridge, Botanic House, 100 Hills Road, Cambridge CB2 1PH

10:55 AM 12:05 PM PITCH 2: STEVENAGE BIOSCIENCE CATALYST Investor showcase + networking Deloitte, One, Station Square, Cambridge CB12GA

12:05 PM 1:00 PM LUNCH & NETWORKING Deloitte, One, Station Square, Cambridge CB12GA

1:20 PM - 2:35 PM PITCH 3: ACCELERATE CAMBRIDGE

Investor showcase + networking Cambridge Judge Business School, Trumpington St, Cambridge CB2 1AG

3:05 PM-4:20 PM PITCH 4: 02H VENTURES + MELTWIND + CANCER RESEARCH HORIZONS Investor showcase + networking Hauxton House, Mill SciTech Park, Mill Lane Hauxton, Cambridge CB22 5HX

4:45 PM-6:30 PM

PITCH 5: BIO-SPARK Investor showcase + networking Newnham College, University of Cambridge, Sidgwick Ave, Cambridge CB3 9DF

COMMUNITY

6:30 PM - 8:00 PM

DRINKS RECEPTION HOSTED BY BIO-SPARK (INVITE ONLY) Drinks and networking reception The LAB, 90 Regent St, Cambridge CB2 1DP

TUESDAY 16TH JUNE

VENTURES TOUR - CAMBRIDGE (DAY 2)

8:45 AM - 9:45 AM INWARD INVESTORS BREAKFAST (INVITE ONLY) Welcome speech, registration and breakfast

The Glasshouse, Innovate Cambridge, Botanic House, 100 Hills Road, Cambridge CB2 1PH

9:45 AM - 10:55 AM PITCH 1: CAMBRIDGE INNOVATION CAPITAL + START CODON

Investor showcase + networking The Glasshouse, Innovate Cambridge, Botanic House, 100 Hills Road, Cambridge CB2 1PH

11:00 AM - 12:10 PM

PITCH 2: CAMBRIDGE ANGELS Investor showcase + networking Deloitte, One, Station Square, Cambridge CB1 2GA

12:10 PM - 1:10 PM LUNCH & NETWORKING Deloitte, One, Station Square, Cambridge CB1 2GA

1:10 PM 2:10 PM PITCH 3: INNOVATE UK BUSINESS GROWTH Investor showcase + networking Deloitte, One, Station Square, Cambridge CB1 2GA

2:15 PM - 3:30 PM PITCH 4: CAMBRIDGE ENTERPRISE + PARK WALK Investor showcase networking The Glasshouse, Innovate Cambridge, Botanic House, 100 Hills Road, Cambridge CB2 1PH

4:00 PM - 5:25 PM PITCH 5:

ACCELERATE@BABRAHAM Investor showcase + networking

Hilton Cambridge City Centre, 20 Downing St, Cambridge CB2 3DT

COMMUNITY

5:30 PM - 7:30 PM

DRINKS RECEPTION HOSTED BY AFFINIA (INVITE ONLY)

Drinks and networking reception Hilton Cambridge City Centre, 20 Downing St, Cambridge CB2 3DT

OPEN DAY

9:00 AM - 10:00 AM

CWOD COMMUNITY BREAKFAST (INVITE ONLY)

Community breakfast to launch Cambridge Wide Open Day Season 4 Clayton Hotel Cambridge, 27-29 Station Rd, Cambridge CB1 2FB

11:00 AM - 3:00 PM

CAMBRIDGE WIDE OPEN DAY

Tours, Company Showcase, Masterclasses & Cocktail Party. See Cambridge life sciences in one shot Cambridge

9:00 AM - 10:30 AM

CFFN: BREAKFAST ROUNDTABLE The Build Begins: Navigating Early Hurdles Building in Life Science

The Press, Station Rd, Foxton, Cambridge CB22 6SA

12:30 PM - 3:00 PM STEVENAGE BIOSCIENCE CATALYST: TOUR AND PANEL

SBC will host a tour of the campus, followed by a panel talk and lunch

Stevenage Bioscience Catalyst, Gunnels Wood Rd, Stevenage SG1 2FX

9:00 AM - 3:30 PM

CREATIVE DISRUPTION FORUM (PAID)

The latest dealmaking and investment strategies that work

Mills & Reeve, Botanic House, 100 Hills Road, Cambridge CB2 1PH

SOCIAL

4:00 PM ONWARDS GARDEN PARTY

A buzzing summer garden party with music, food, drinks & ice-creams!

Hauxton House, Mill SciTech Park, Mill Lane Hauxton, Cambridge CB22 5HX

• THURSDAY 18TH JUNE
• TECHBIO, BIOTECH & PHARMA
• 8:00 AM - 12:00 PM
• BIA TECHBIO X (PAID)

Join the BIA's thriving TechBio community for engaging discussions, valuable insights and dynamic networking

The Discovery Centre - AstraZeneca, Biomedical Campus, 1 Francis Crick Ave, Trumpington, Cambridge CB2 0AA

12:30 PM - 7:30 PM

ASTRAZENECA EXCHANGE An event dedicated to supporting networking and celebrating collaboration within the UK Life Sciences ecosystem

The Discovery Centre - AstraZeneca, Biomedical Campus, 1 Francis Crick Ave, Trumpington, Cambridge CB2 OAA

10:00 AM - 4:30 PM

CREATIVE DISRUPTION FORUM (PAID) Modern Drug Discovery-The latest strategies The National Institute of Agricultural Botany, 93 Lawrence Weaver Road, Cambridge CB3 OLE

6:00 PM - 8:30 PM

CONEXEN LIFE SCIENCES COMMUNITY EVENT (PAID)

Community and networking for professionals and founders in biopharma, life sciences, and health tech in Cambridge

Merlin Place, Milton Road, Cambridge, CB4 ODP

6:00 PM 8:00 PM

MORE RESEARCH, LESS CANCER - CANCER RESEARCH UK EVENT Exclusive event to explore how global innovation is accelerating progress in cancer research and treatment

Cancer Research UK Cambridge Institute University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 ORE

CW powered by 02h community title sponsor

• MILLS & REEVE
• Achieve more. Together.
• FRIDAY 19TH JUNE
• COMMUNITY DAY
• 10:00 AM - 2:00 PM

FORM THE FUTURE-INSPIRING FUTURE STEM WORKFORCE

Form the Future will be working with Cambridge Research Park who will be opening their doors to inspire students from Cambridge primary schools. From high-spec labs to fully- equipped business suites, the students will meet the employers onsite, engage with STEM activities and learn what goes on behind the normally closed doors of a research park. Cambridge Research Park, Cambridge CB25 9TL

• FRINGE EVENTS
• 10:00 AM - 5:30 PM
• WED 10TH JUNE
• CREATIVE DISRUPTION FORUM - OXFORD (PAID)

The Future of Neuro Therapeutics and CNS Health Innovations

The Magdalen Centre, 1 Robert Robinson Avenue Littlemore OX4 4GA

10:30 AM - 3:30 PM

THU 11TH JUNE

3C - CAMBRIDGE | CMC | CDMO (INVITE ONLY)

Maximizing Value from an Early Stage

The Glasshouse, Innovate Cambridge, 100 Hills Road, Cambridge CB2 1AR

• 9:00 AM - 6:00 PM
• SAT 13TH JUNE
• BIOTECH BIKERS

Bringing together biopharma, biotech, bioscience, and healthcare professionals who share a passion for cycling.

Hauxton House, Mill SciTech Park, Mill Lane Hauxton, Cambridge CB22 5HX

• Working
• Ways
• JUNE

EXPLORE THE CITY’S LIFE SCIENCES ECOSYSTEM IN ONE DAY!

community

Driving Net Zero: ESG-Driven Tree Planting Surpasses 100K Milestone...

o2h group encourages contribution, partnerships and connections with local NGO’s and the community

We understand that we have a contribution to make to the community in which we do our work, not at some unspecified point in the future, but now, and as part of our life journey, however small that contribution is. o2h group encourages collaboration, partnerships, and connections with local NGOs as well as communities. The first stage is always to establish a personal connection based not on solving anyone’s problems, but on giving one’s love, time, and energy.

The second stage is to explore ways in which we can add value to their lives by deploying our skills. We have been active with a number of local organisations, including – Manav Sadhna, VSSM, India Recycles, Shelter for Children with HIV, old age homes such as Jivandhara, organisations supporting women’s rights in disadvantaged areas of the city, The Blind People’s Association and many more.

Inspiring Scientific Curiosity: Lab workshops for young locals

we believe to build a company we first build our culture

HUNT

Insight-Driven Science

State-of-the-art research centres in Cambridge, UK and Ahmedabad, India

Mill scitech park Mill lane Hauxton Cambridge CB22 5HX

USA

CIC Cambridge 1 Broadway Cambridge MA 02142

In dia

Sharmista Research Centre 35, Panchratna Ind. Estate Changodar, Sarkhej Bavla Road Ahmedabad Gujarat 382213

Scan and Discover More

For more information or to get a quote contact us at: [email protected] o2h-discovery o2hgroup o2hlife o2h_discovery

1st September 2026